

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

CONVENIENCE TRANSLATION INTO ENGLISH OF  
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE INTERIM PERIOD 1 JANUARY - 30 JUNE 2016  
TOGETHER WITH INDEPENDENT AUDITOR'S REVIEW REPORT

(ORIGINALLY ISSUED IN TURKISH)



**CONVENIENCE TRANSLATION INTO ENGLISH OF INDEPENDENT  
AUDITOR'S REVIEW REPORT ORIGINALLY ISSUED IN TURKISH**  
**REPORT ON REVIEW OF INTERIM CONDENSED CONSOLIDATED  
FINANCIAL INFORMATION**

To the Board of Directors of Ülker Bisküvi Sanayi A.Ş.

*Introduction*

1. We have reviewed the accompanying interim condensed consolidated balance sheet of Ülker Bisküvi Sanayi A.Ş. (the "Company") and its subsidiaries (collectively referred as the "Group") as at 30 June 2016 and the related interim condensed consolidated statements of comprehensive income, changes in equity and cash flows for the six-month period then ended. The management of the Group is responsible for the preparation and fair presentation of this interim condensed consolidated financial information in accordance with Turkish Accounting Standard 34 ("TAS 34") "Interim Financial Reporting". Our responsibility is to express a conclusion on this interim condensed consolidated financial information based on our review.

*Scope of review*

2. We conducted our review in accordance with the Standard on Review Engagements ("SRE") 2410, "Review of interim financial information performed by the independent auditor of the entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and the objective of which is to express an opinion on the financial statements. Consequently, a review on the interim financial information does not provide assurance that the audit firm will be aware of all significant matters which would have been identified in an audit. Accordingly, we do not express an audit opinion.

*Conclusion*

3. Based on our review, nothing has come to our attention that causes us to conclude that the accompanying interim condensed consolidated financial information of Ülker Bisküvi Sanayi A.Ş. and its subsidiaries is not prepared, in all material respects, in accordance with TAS 34.

Başaran Nas Bağımsız Denetim ve  
Serbest Muhasebeci Mali Müşavirlik A.Ş.  
a member of  
PricewaterhouseCoopers

Mert Tütün, SMMM  
Partner

Istanbul, 16 August 2016

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS  
FOR THE INTERIM PERIOD 1 JANUARY – 30 JUNE 2016**

---

CONTENTS	PAGE(S)
CONDENSED CONSOLIDATED BALANCE SHEETS.....	1-2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME .....	3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME .....	4
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY .....	5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS.....	6-7
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.....	7-42
NOTE 1 ORGANIZATION AND OPERATIONS OF THE GROUP .....	7-8
NOTE 2 BASIS OF PRESENTATION OF FINANCIAL STATEMENTS .....	8-16
NOTE 3 BUSINESS COMBINATIONS .....	17-19
NOTE 4 SEGMENTAL INFORMATION .....	19
NOTE 5 CASH AND CASH EQUIVALENTS .....	20
NOTE 6 FINANCIAL INVESTMENTS .....	20
NOTE 7 FINANCIAL LIABILITIES.....	21-22
NOTE 8 TRADE RECEIVABLES AND PAYABLES.....	23
NOTE 9 OTHER RECEIVABLES AND PAYABLES.....	24
NOTE 10 INVENTORIES.....	24
NOTE 11 INVESTMENT PROPERTIES .....	25
NOTE 12 PROPERTY, PLANT AND EQUIPMENT .....	26-28
NOTE 13 INTANGIBLE ASSETS .....	28-29
NOTE 14 PROVISIONS, CONTINGENT ASSETS AND LIABILITIES .....	30
NOTE 15 REVENUE AND COST OF SALES .....	30
NOTE 16 EXPENSES BY NATURE .....	31
NOTE 17 FINANCIAL INCOME.....	31
NOTE 18 FINANCIAL EXPENSES.....	31
NOTE 19 TAX ASSETS AND LIABILITIES .....	32-33
NOTE 20 EARNINGS PER SHARE .....	34
NOTE 21 BALANCES AND TRANSACTIONS WITH RELATED PARTIES.....	34-38
NOTE 22 NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS.....	39-41
NOTE 23 FINANCIAL INSTRUMENTS .....	41-42
NOTE 24 EVENTS AFTER THE BALANCE SHEET DATE.....	42

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS AS OF 30 JUNE 2016 AND 31 DECEMBER 2015**

(Amounts expressed in Turkish Lira (“TRY”) unless otherwise stated.)

ASSETS	Notes	Restated (*)	
		Reviewed Current Period 30 June 2016	Audited Previous Period 31 December 2015
<b>Current Assets</b>		<b>2,974,850,855</b>	<b>3,464,818,108</b>
Cash and Cash Equivalents	5	1,745,714,298	1,344,387,882
Financial Investments	6	582,728	704,437
Trade Receivables			
- Due From Related Parties	8-21	532,913,132	572,853,651
- Other Trade Receivables	8	163,837,926	190,547,613
Other Receivables			
- Due From Related Parties	9-21	150,803	786,329,934
- Other Receivables	9	37,620,738	37,263,138
Inventories	10	300,266,762	318,503,976
Prepaid Expenses			
- Prepaid Expenses to Related Parties		103,146,776	112,601,084
- Prepaid Expenses to Third Parties		48,906,630	55,441,210
Corporate Income Tax Assets		457	825,280
Other Current Assets		41,710,605	45,359,903
<b>Non-Current Assets</b>		<b>1,801,397,325</b>	<b>1,723,797,220</b>
Financial Investments	6	768,270,313	765,334,184
Trade Receivables			
- Due From Related Parties	8-21	6,220,760	6,196,664
Other Receivables			
- Other Receivables	9	178,097	176,911
Investment Properties	11	12,893,377	12,904,161
Property, Plant and Equipment	12	971,426,372	891,477,307
Intangible Assets	13	1,462,834	1,808,877
Prepaid Expenses		23,120,513	28,562,343
Deferred Tax Assets	19	17,825,059	17,332,587
Other Non-Current Assets		-	4,186
<b>TOTAL ASSETS</b>		<b>4,776,248,180</b>	<b>5,188,615,328</b>

(\*) Restatement effects have been explained in Note 2.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS AS OF 30 JUNE 2016 AND 31 DECEMBER 2015**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

<b>LIABILITIES</b>	<b>Notes</b>	<b>Reviewed</b>	<b>Restated</b>
		<b>Current Period</b>	<b>(*)Audited Previous Period</b>
		<b>30 June 2016</b>	<b>31 December 2015</b>
<b>Current Liabilities</b>		<b>1.238.618.709</b>	<b>1.784.292.054</b>
Short Term Financial Liabilities	7	602.053.225	924.954.546
Short Term Portion of Long-Term Financial Liabilities	7	22.638.717	34.835.819
Trade Payables			
- Due to Related Parties	8-21	255.724.837	309.288.490
- Other Trade Payables	8	203.340.929	284.598.178
Employee Benefit Related Liabilities		26.438.072	27.331.047
Other Payables			
- Due to Related Parties	21	-	86.239.625
- Other Payables		3.404.819	4.598.311
Deferred Revenue		16.896.372	39.895.543
Current Income Tax Liabilities	19	27.601.953	9.514.388
Short Term Provisions			
- Provisions for Employee Benefits		23.462.763	27.381.056
- Other Short Term Provisions		45.309.010	23.881.447
Other Current Liabilities		11.748.012	11.773.604
<b>Non-Current Liabilities</b>		<b>1.854.019.137</b>	<b>1.807.684.924</b>
Long Term Financial Liabilities	7	1.776.743.299	1.735.320.937
Long Term Provisions			
- Provisions for Employment Benefits		41.258.416	37.439.337
Deferred Tax Liabilities	19	36.017.422	34.924.650
<b>SHAREHOLDERS' EQUITY</b>		<b>1.683.610.334</b>	<b>1.596.638.350</b>
<b>Equity Attributable To Equity Holders' of the Parent</b>		<b>1.466.902.463</b>	<b>1.386.766.049</b>
Share Capital		342.000.000	342.000.000
Inflation Adjustments on Equity Items		108.056.201	108.056.201
Accumulated Other Comprehensive Income/Expense			
not to be Reclassified Under Profit and Loss			
- Actuarial Loss on Post-Employment Termination Benefit Obligation		(1.442.253)	(410.636)
- Increases on Revaluation Plant, Property and Equipment		5.231.735	5.231.735
Accumulated Other Comprehensive Income/Expense to be Reclassified Under Profit and Loss			
- Gains from Financial Assets Measured at Fair Value through Other Comprehensive Income		542.525.618	539.968.646
- Currency Translation Adjustments		(5.381.335)	-
Restricted Reserves Appropriated from Profits		119.806.833	112.116.833
Retained Earnings		178.113.270	(17.983.954)
Net Profit For The Period		177.992.394	297.787.224
<b>Non-Controlling Interest</b>		<b>216.707.871</b>	<b>209.872.301</b>
<b>TOTAL LIABILITIES AND EQUITY</b>		<b>4.776.248.180</b>	<b>5.188.615.328</b>

(\*) Restatement effects have been explained in Note 2.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF INCOME FOR THE INTERIM PERIODS ENDED 30 JUNE 2016 AND 2015**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Reviewed Current Period 1 January - 30 June 2016	Restated (*) Current Period 1 April - 30 June 2016	Restated (*) Reviewed Previous Period 1 January - 30 June 2015	Restated (*) Previous Period 1 April - 30 June 2015
Revenue	15	1.980.545.370	974.247.899	1.915.786.892	934.984.171
Cost of Sales (-)	15	(1.505.900.240)	(740.031.763)	(1.474.467.897)	(723.774.703)
<b>GROSS PROFIT FROM OPERATIONS</b>		<b>474.645.130</b>	<b>234.216.136</b>	<b>441.318.995</b>	<b>211.209.468</b>
Research Expenses (-)	16	(4.285.020)	(2.202.243)	(3.627.132)	(2.014.559)
Marketing, Sales and Distribution Expenses (-)	16	(181.590.340)	(83.925.581)	(188.490.914)	(78.973.933)
General Administrative Expenses (-)	16	(60.183.703)	(34.190.185)	(54.075.316)	(27.847.107)
Other Operating Income		35.673.139	15.100.968	56.599.660	20.798.839
Other Operating Expenses (-)		(20.143.731)	(7.331.930)	(42.374.950)	(21.274.832)
<b>OPERATING PROFIT FROM MAIN OPERATIONS</b>		<b>244.115.475</b>	<b>121.667.165</b>	<b>209.350.343</b>	<b>101.897.876</b>
Income from Investment Activities		129.147.515	60.354.103	369.847.757	112.607.034
Expenses from Investment Activities (-)		(81.521.160)	(5.469.156)	(64.650.487)	(10.470.331)
<b>OPERATING PROFIT BEFORE FINANCIAL INCOME AND EXPENSES</b>		<b>291.741.830</b>	<b>176.552.112</b>	<b>514.547.613</b>	<b>204.034.579</b>
Financial Income	17	96.089.103	14.511.438	23.815.710	6.294.256
Financial Expenses (-)	18	(141.559.344)	(71.002.412)	(371.447.528)	(116.075.497)
<b>PROFIT BEFORE TAX</b>		<b>246.271.589</b>	<b>120.061.138</b>	<b>166.915.795</b>	<b>94.253.338</b>
<b>Tax Expense</b>	19	<b>(48.022.457)</b>	<b>(22.864.699)</b>	<b>(28.618.636)</b>	<b>(15.633.472)</b>
Tax on Income (-)		(47.301.572)	(25.942.296)	(36.483.024)	(16.750.396)
Deferred Tax (Expense) / Income		(720.885)	3.077.597	7.864.388	1.116.924
<b>PROFIT FOR THE PERIOD</b>		<b>198.249.132</b>	<b>97.196.439</b>	<b>138.297.159</b>	<b>78.619.866</b>
<b>Distribution of the Profit for the Period</b>					
Non-Controlling Interest		20.256.738	9.998.747	16.252.272	7.144.405
Equity Holders of the Parent		177.992.394	87.197.692	122.044.887	71.475.461
<b>Earnings Per Share</b>	20	0,52	0,25	0,36	0,21

(\*) Resatement effects have been explained in Note 2.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE INTERIM PERIODS ENDED 30 JUNE 2016 AND 2015**  
(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

	Reviewed Current Period 1 January - 30 June 2016	Restated (*) Current Period 1 April - 30 June 2016	Restated (*) Reviewed Previous Period 1 January - 30 June 2015	Restated (*) Reviewed Previous Period 1 April- 30 June 2015
<b>PROFIT FOR THE PERIOD</b>	<b>198.249.132</b>	<b>97.196.439</b>	<b>138.297.159</b>	<b>78.619.866</b>
Other Comprehensive Income:				
Items not to be Reclassified Under Profit and Loss	(1.069.563)	258.737	218.070	100.557
Actuarial Gain/(Loss) on Post-Employment Termination Benefit Obligation	(1.336.954)	323.421	272.588	125.697
Deferred Tax Effect	267.391	(64.684)	(54.518)	(25.140)
Items to be Reclassified Under Profit and Loss	(9.382.252)	(2.437.895)	(1.138.499)	1.053.112
Currency Translation Adjustments	(12.171.575)	379.889	-	-
Change in Revaluation Funds of Financial Assets	2.936.129	(2.966.089)	(1.198.420)	1.108.539
Deferred Tax Effect	(146.806)	148.305	59.921	(55.427)
<b>OTHER COMPREHENSIVE (EXPENSE)/INCOME</b>	<b>(10.451.815)</b>	<b>(2.179.158)</b>	<b>(920.429)</b>	<b>1.153.669</b>
<b>TOTAL COMPREHENSIVE INCOME</b>	<b>187.797.317</b>	<b>95.017.281</b>	<b>137.376.730</b>	<b>79.773.535</b>
Distribution of Total Comprehensive Income				
Non-Controlling Interest	13.660.903	9.750.184	16.221.921	7.206.326
Equity Holders of the Parent	174.136.414	85.267.097	121.154.809	72.567.209

(\*) Restatement effects have been explained in Note 2.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY FOR THE PERIOD ENDED 30 JUNE 2016  
AND 2015**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

	Accumulated Other Comprehensive Income/Expenses To Be Reclassified Under Profit And Loss	Other Comprehensive Income/Expenses Not To Be Reclassified Under Profit And Loss	Accumulated Profit
<b>Share Capital</b>	<b>Inflation Adjustments to Share Capital</b>	<b>Financial Assets Measured at Fair Value</b>	<b>Actuarial Loss on Post-Employment Termination Benefit Obligation</b>
<b>As of 1 January 2015</b>	<b>342,000,000</b>	<b>108,056,201</b>	<b>5,231,735</b>
Total comprehensive income	-	(1,043,662)	(695,347)
Dividend paid (*)	-	-	-
Transfer	-	-	-
<b>As of 30 June 2015</b>	<b>342,000,000</b>	<b>108,056,201</b>	<b>5,231,735</b>
			(410,636)
			112,116,833
			122,044,887
			161,340,007
			1,164,757,808
			103,428,948
			<b>1,268,186,756</b>
<b>As of 1 January 2016 (Restated)</b>	<b>342,000,000</b>	<b>108,056,201</b>	<b>539,968,646</b>
Total comprehensive income	-	2,556,972	(5,381,335)
Dividend paid (**)	-	-	-
Transfer	-	-	-
<b>As of 30 June 2016</b>	<b>342,000,000</b>	<b>108,056,201</b>	<b>542,525,618</b>
			(5,381,335)
			5,231,735
			(1,442,253)
			119,806,833
			177,992,394
			178,113,270
			1,466,902,463
			216,707,871
			<b>1,683,610,334</b>

(\*) At the General Assembly Meeting for the year of 2014 held on 26 March 2015, it has been resolved to distribute TRY 94,000,000 as cash and fully funded by the profit for the year and started to be distributed as of April 7th 2015.

(\*\*) At the General Assembly Meeting for the year of 2015 held on 24 March 2016, it has been resolved to distribute TRY 94,000,000 as cash and fully funded by the profit for the year and started to be distributed as of April 5th 2016.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIOD ENDED 30 JUNE 2016 AND 2015**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Reviewed Current Period	Restated Reviewed Previous Period
		1 January-30 June 2016	1 January-30 June 2015
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Net profit for the period		198.249.132	138.297.159
Adjustments to reconcile net profit / (loss) to net cash provided by operating activities			
Adjustment for depreciation and amortization expenses			
Depreciation expenses of tangible assets	11-12	39.021.493	36.207.977
Amortization expenses of intangible assets	13	495.351	571.939
Adjustment for impairment loss			
Adjustment for impairment loss of other financial investments		121.709	(10.030)
Adjustment for impairment loss of inventories	10	2.767.005	807.257
Adjustment for provisions			
Adjustments for provisions related with employee benefits			
Provision for employment benefits		14.333.721	9.503.796
Provision for unused vacation rights		5.740.202	4.603.614
Performance premium provision		7.214.201	4.358.843
Adjustments for other provisions			
Allowance for doubtful receivables	8	411.980	140.629
Provision for sales return		492.962	6.899.399
Change in other provisions (net)		19.725.962	12.361.843
Adjustment for lawsuit provisions		1.211.527	27.071
Adjustment for dividend income		(359.526)	(299.605)
Adjustment for interest income/(expenses)			
Adjustment for interest income		(39.741.799)	(27.542.840)
Adjustment for interest expenses			
Discount expenses (net)		664.022	4.892.680
Interest expenses		40.449.797	32.213.850
Adjustment for tax expenses	19	48.022.457	28.618.636
Adjustment for gains arised from tangible assets		(465.522)	(161.384)
Other adjustments for which cash effects are investing or financing cash flow			
Change in foreign currency and interest expenses of financial liabilities (net)		4.100.864	311.499.867
Change in foreign currency from investing activities (net)		(4.048.935)	(291.553.055)
Commission expenses and finance service income (net)		919.580	3.918.101
Other adjustments to reconcile profit (loss)			
Rent income		(3.729.467)	(3.742.230)
<b>Net Operating cash flows provided before changes in working capital</b>		<b>335.596.716</b>	<b>271.613.517</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIOD ENDED 30 JUNE 2016 AND 2015**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Reviewed Current Period	Restated Reviewed Previous Period
		1 January-30 June 2016	1 January-30 June 2015
<b>Changes in Working Capital</b>			
Decrease in trade receivables		24.119.100	24.687.636
Decrease in trade receivables from related parties		40.764.235	22.714.376
Decrease/ (Increase) in inventories		15.470.209	(14.429.732)
Decrease in other receivables and other current assets		24.725.416	36.478.101
Decrease in trade payables		(81.998.107)	(103.231.362)
Decrease in trade payables to related parties		(54.234.377)	(49.397.939)
Decrease in other payables and liabilities		(25.115.801)	(14.640.876)
<b>Net cash generated from operations</b>		<b>279.327.391</b>	<b>173.793.721</b>
Taxes paid		(28.389.184)	(26.023.879)
Payments Related with Provisions for Employee Benefits			
Employment termination benefit paid		(11.543.724)	(6.742.149)
Unused vacation rights paid		(4.582.625)	(2.924.351)
Performance premium paid		(12.285.501)	(7.536.598)
Lawsuits provision paid		(2.888)	(315.531)
Collections from doubtful trade receivables	8	1.653	7.686
<b>Net cash generated from operating activities</b>		<b>222.525.122</b>	<b>130.258.899</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Acquisitions of tangible assets	12	(134.826.775)	(64.128.520)
Acquisitions of intangible assets	13	(84.272)	(517.042)
Proceeds from sales of tangible and intangible assets		1.375.567	1.309.591
Changes in non-trade receivables from related parties		786.179.132	13.635.259
Rent income		3.729.467	3.742.230
Dividend received		359.526	299.605
Interest received		39.741.799	23.239.189
<b>Net cash received from/(used in) investing activities</b>		<b>696.474.444</b>	<b>(22.419.688)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Loan repayment		(651.084.801)	(16.444.595)
Loans acquired		350.223.038	101.645.390
Change in leasing liabilities		(175.509)	(59.895)
Dividend paid		(100.825.333)	(99.158.667)
Interest paid		(33.619.855)	(29.237.936)
Changes in non-trade payables to related parties		(86.239.625)	-
<b>Net cash used in financing activities</b>		<b>(521.722.085)</b>	<b>(43.255.703)</b>
<b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b>		<b>397.277.481</b>	<b>64.583.508</b>
<b>THE EFFECT OF FOREIGN EXCHANGE RATE CHANGE ON CASH AND CASH EQUIVALENTS</b>		<b>4.048.935</b>	<b>108.383.787</b>
<b>CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD</b>	5	<b>1.344.387.882</b>	<b>1.033.829.882</b>
<b>CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD</b>	5	<b>1.745.714.298</b>	<b>1.206.797.177</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİŞKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**1. ORGANIZATION AND OPERATIONS OF THE GROUP**

Ülker Bisküvi Sanayi A.Ş. ("the Company") and its subsidiaries (all together "the Group"), comprises of the parent Ülker Bisküvi Sanayi A.Ş. ("the Company") and ten subsidiaries in which the Company owns the majority share of the capital or which are controlled by the Company (2015: four).

Ülker Bisküvi Sanayi A.Ş. was established in 1944. The Company's core business activities are manufacturing of biscuits, chocolate, chocolate coated biscuits, wafers and cakes.

Ülker Bisküvi Sanayi A.Ş. which is registered at the Capital Market Board, merged under its own title with Anadolu Gıda Sanayi A.Ş., whose shares have been quoted on Borsa İstanbul since 30 October 1996, as of 31 December 2003.

The headquarter of Ülker Bisküvi Sanayi A.Ş. is located Kısıklı Mah. Ferah Cad. No:1 Büyük Çamlıca Üsküdar / İstanbul.

As of 30 June 2016, the total number of people employed by the Group is 8.823, which contains 1.008 employees who worked as subcontractors (31 December 2015: 7.341, subcontractor: 811).

The ultimate parent and the controlling party of the Group is Yıldız Holding A.Ş. The ultimate parent of Yıldız Holding A.Ş. is managed by Ülker Family.

As of 30 June 2016 and 31 December 2015, the names and percentages of the shareholders holding more than 10% of the Company's share capital are as follows:

Name of the Shareholders	Share	30 June 2016		31 December 2015	
		Percentage	Share	Percentage	Share
Yıldız Holding A.Ş.	168.124.482	%49,16	168.124.482	%49,16	
Yıldız Holding A.Ş. Subsidiaries and Ülker Family	27.738.115	%8,11	27.738.115	%8,11	
Other	146.137.403	%42,73	146.137.403	%42,73	
	<b>342.000.000</b>	<b>%100,00</b>	<b>342.000.000</b>	<b>%100,00</b>	

As of 30 June 2016 and 31 December 2015, the details of the subsidiaries under full consolidations in terms of direct and effective share of ownership and principal business activities are as follows:

Subsidiaries	30 June 2016		31 December 2015		Nature of Operations
	Ratio of Direct Ownership %	Ratio of Effective Ownership %	Ratio of Direct Ownership %	Ratio of Effective Ownership %	
Biskot Bisküvi Gıda Sanayi ve Ticaret A.Ş.	%73,9	%73,9	%73,9	%73,9	Manufacturing
Ülker Çikolata Sanayi A.Ş.	%91,7	%91,7	%91,7	%91,7	Manufacturing
Atlas Gıda Pazarlama Sanayi ve Ticaret A.Ş.	%100,0	%100,0	%100,0	%100,0	Trading
Reform Gıda Paz. San. ve Tic. A.Ş.	%100,0	%100,0	%100,0	%100,0	Trading
İstanbul Gıda Dış Ticaret A.Ş. (*)	%100,0	%100,0	-	-	Export
UI Egypt B.V. (**)	%51,0	%51,0	-	-	Investing
Hi-Food for Advanced Food Industries (**)	-	%45,9	-	-	Manufacturing
Sabourne Investments Ltd (***)	%100,0	%100,0	-	-	Investing
Food Manufacturers' Company (***)	-	%55,0	-	-	Manufacturing
Food Manufacturers' Company for Distribution (****)	-	%52,3	-	-	Export

(\*) The Company purchased 20.250.000 shares of İstanbul Gıda Dış Ticaret A.Ş. from Yıldız Holding A.Ş., who is 100% shareholder, for an amount of TRY 43 million as of 31 March 2016.

(\*\*) The Company purchased 51.0% shares of UI Egypt B.V., operating in Netherlands, from Yıldız Holding A.Ş. for an amount of USD 30 million as of 31 March 2016. As a result of the transaction, the Company has gained the controlling power in UI Egypt B.V. and Hi Food for Advanced Food Industries, which UI Egypt B.V. has 90% shares.

(\*\*\*) The Company purchased 100.0% shares of Sabourne Investments Limited., from Yıldız Holding A.Ş. for an amount of USD 50 million as of 27 June 2016. As a result of the transaction, the Company has gained the controlling power in Food Manufacturers' Company, which Sabourne Investments Limited has 55.0% shares and the controlling power in Food Manufacturers' Company for Distribution, which Food Manufacturers' Company has 95.0% shares.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira (“TRY”) unless otherwise stated.)

---

**1. ORGANIZATION AND OPERATIONS OF THE GROUP (cont'd)**

*Dividend Paid:*

The Company has paid a dividend amount of TRY 94.000.000 (2015: TRY 94.000.000) in the current period. Dividend per share is TRY 0.27 (2015: TRY 0.27).

*Approval of Financial Statements:*

The Board of Directors has approved the financial statements and given authorization for the issuance on 16 August 2016. The General Assembly has the authority to amend/modify the financial statements.

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS**

**2.1 Basis of the presentation:**

**Principles for Preparation of Financial Statements and Significant Accounting Policies**

The accompanying consolidated financial statements are prepared in accordance with Communiqué Serial II, No:14.1, “Principles of Financial Reporting in Capital Markets” (“the Communiqué”) published in the Official Gazette numbered 28676 on 13 June 2013. According to Article 5 of the Communiqué, consolidated financial statements are prepared in accordance with the Turkish Accounting Standards (“TAS”) issued by Public Oversight Accounting and Auditing Standards Authority (“POAASA”). TAS contains Turkish Accounting Standards, Turkish Financial Reporting Standards (“TFRS”) and its addendum and interpretations (“IFRIC”).

The consolidated financial statements of the Group are prepared as per the CMB announcement of 7 June 2013 relating to financial statements presentations. Comparative figures are reclassified, where necessary, to conform to changes in the presentation of the current year's consolidated financial statements.

In accordance with the CMB resolution issued on 17 March 2005, listed companies operating in Turkey are not subject to inflation accounting effective from 1 January 2005. Therefore, the consolidated financial statements of the Group have been prepared accordingly.

The Company maintain their books of accounts and prepare their statutory financial statements in accordance with the Turkish Commercial Code (“TCC”), tax legislation, the Uniform Chart of Accounts issued by the Ministry of Finance and principles issued by CMB. The foreign subsidiaries maintain their books of account in accordance with the laws and regulations in force in the countries in which they are registered. These consolidated financial statements have been prepared under historical cost conventions except for financial assets and financial liabilities which are carried at fair value. The consolidated financial statements are based on the statutory records, which are maintained under historical cost conventions, with the required adjustments and reclassifications reflected for the purpose of fair presentation in accordance with TAS.

In accordance with the TAS, the entities are allowed to prepare a complete or condensed set of interim financial statements in accordance with TAS 34, “Interim Financial Reporting”. In this respect the Group preferred to present its interim condensed consolidated financial statements. The Group's interim condensed consolidated financial statement does not include all disclosures and notes that should be included at year-end financial statements. Therefore the interim condensed consolidated financial statements should be examined together with the year-end financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

---

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (cont'd)**

**2.1 Basis of the presentation (cont'd)**

**Principles for Preparation of Financial Statements and Significant Accounting Policies**

**Functional and presentation currency**

Financial statements of each subsidiary of the Group are presented in the currency of the primary economic environment in which the entities operate (its functional currency). The results and financial position of the each subsidiary are expressed in Turkish Lira, which is the functional and presentation currency of the Group.

As of 30 June 2016, rates declared by Central Bank of Republic of Turkey are; 1 Euro = TRY 3,2044, 1 USD = TRY 2,8936 (31 December 2015: 1 Euro = TRY 3,1776, 1 USD = TRY 2,9076). For the period between January 1, 2016 and June 30 2016, average rates declared by Central Bank of Republic of Turkey are 1 Euro = TRY 3,2558, 1 USD = TRY 2,9181 (January 1, 2015 and June 30, 2015: 1 Euro = TRY 2,8588, 1 USD = TRY 2,5611).

**2.2 Adoption of New and Revised International Financial Reporting Standards:**

The Group has implemented new and revised standards, amendments and interpretations which were effective from 1 January 2016 and related with own activity.

**Standards, amendments and interpretations applicable as at 30 June 2016:**

- Amendment to IFRS 11, "Joint arrangements" on acquisition of an interest in a joint operation, effective from annual periods beginning on or after 1 January 2016. This amendment adds new guidance on how to account for the acquisition of an interest in a joint operation that constitutes a business. The amendments specify the appropriate accounting treatment for such acquisitions.
- Amendments to IAS 16 "Property, plant and equipment", and IAS 41, "Agriculture", regarding bearer plants, effective from annual periods beginning on or after 1 January 2016. These amendments change the financial reporting for bearer plants, such as grape vines, rubber trees and oil palms. It has been decided that bearer plants should be accounted for in the same way as property, plant and equipment because their operation is similar to that of manufacturing. Consequently, the amendments include them within the scope of IAS 16, instead of IAS 41. The produce growing on bearer plants will remain within the scope of IAS 41.
- Amendment to IAS 16, "Property, plant and equipment" and IAS 38, "Intangible assets", on depreciation and amortisation, effective from annual periods beginning on or after 1 January 2016. In this amendment the it has clarified that the use of revenue based methods to calculate the depreciation of an asset is not appropriate because revenue generated by an activity that includes the use of an asset generally reflects factors other than the consumption of the economic benefits embodied in the asset. It is also clarified that revenue is generally presumed to be an inappropriate basis for measuring the consumption of the economic benefits embodied in an intangible asset.
- IFRS 14 "Regulatory deferral accounts", effective from annual periods beginning on or after 1 January 2016. IFRS 14, "Regulatory deferral accounts" permits first-time adopters to continue to recognise amounts related to rate regulation in accordance with their previous GAAP requirements when they adopt IFRS. However, to enhance comparability with entities that already apply IFRS and do not recognise such amounts, the standard requires that the effect of rate regulation must be presented separately from other items.
- Amendments to IAS 27, "Separate financial statements" on the equity method, effective from annual periods beginning on or after 1 January 2016. These amendments allow entities to use the equity method to account for investments in subsidiaries, joint ventures and associates in their separate financial statements.
- Amendments to IFRS 10 "Consolidated financial statements" and IAS 28, "Investments in associates and joint ventures", effective from annual periods beginning on or after 1 January 2016. These amendments clarify the application of the consolidation exception for investment entities and their subsidiaries.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira (“TRY”) unless otherwise stated.)

---

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (cont’d)**

**2.2 Adoption of New and Revised International Financial Reporting Standards:**

**Standards, amendments and interpretations applicable as at 30 June 2016 (cont’d)**

- Annual improvements 2014, effective from annual periods beginning on or after 1 January 2016. These set of amendments impacts 4 standards:
  - IFRS 5, “Non-current assets held for sale and discontinued operations” regarding methods of disposal.
  - IFRS 7, “Financial instruments: Disclosures”, (with consequential amendments to IFRS 1) regarding servicing contracts.
  - IAS 19, “Employee benefits” regarding discount rates.
  - IAS 34, “Interim financial reporting” regarding disclosure of information.
- Amendment to IAS 1, “Presentation of financial statements” on the disclosure initiative, effective from annual periods beginning on or after 1 January 2016, these amendments are as part of the IASB initiative to improve presentation and disclosure in financial reports.
- Amendment to IFRS 10 “Consolidated financial statements” and IAS 28, “Investments in associates and joint ventures”, effective from annual periods beginning on or after 1 January 2016. These amendments clarify the application of the consolidation exception for investment entities and their subsidiaries.

**Standards, amendments and interpretations effective after 30 June 2016:**

- Amendments to IAS 7 “Statement of cash flows” on disclosure initiative, effective from annual periods beginning on or after 1 January 2017. These amendments introduce an additional disclosure that will enable users of financial statements to evaluate changes in liabilities arising from financing activities. The amendment is part of the IASB’s Disclosure Initiative, which continues to explore how financial statement disclosure can be improved.
- Amendments IAS 12 “Income Taxes”, effective from annual periods beginning on or after 1 January 2017. The amendments clarify the accounting for deferred tax where an asset is measured at fair value and that fair value is below the asset’s tax base. It also clarify certain other aspects of accounting for deferred tax assets.
- Amendments to IFRS 2, “Share based payments” on clarifying how to account for certain types of share-based payment transactions, effective from annual periods beginning on or after 1 January 2018. This amendment clarifies the measurement basis for cash-settled, share-based payments and the accounting for modifications that change an award from cash-settled to equity-settled. It also introduces an exception to the principles in IFRS 2 that will require an award to be treated as if it was wholly equity-settled, where an employer is obliged to withhold an amount for the employee’s tax obligation associated with a share-based payment and pay that amount to the tax authority.
- Amendments IFRS 15 “Revenue from contracts with customers”, effective from annual periods beginning on or after 1 January 2018. IFRS 15, “Revenue from contracts with customers” is a converged standard from the IASB and FASB on revenue recognition. The standard will improve the financial reporting of revenue and improve comparability of the top line in financial statements globally.
- Amendments to IFRS 15, ‘Revenue from contracts with customers’, effective from annual periods beginning on or after 1 January 2018. These amendments comprise clarifications of the guidance on identifying performance obligations, accounting for licences of intellectual property and the principal versus agent assessment (gross versus net revenue presentation). New and amended illustrative examples have been added for each of those areas of guidance. The IASB has also included additional practical expedients related to transition to the new revenue standard.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira (“TRY”) unless otherwise stated.)

---

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (cont’d)**

**2.2 Adoption of New and Revised International Financial Reporting Standards:**

**Standards, amendments and interpretations effective after 30 June 2016: (cont’d)**

- IFRS 9 “Financial instruments”, effective from annual periods beginning on or after 1 January 2018. This standard replaces the guidance in IAS 39. It includes requirements on the classification and measurement of financial assets and liabilities; it also includes an expected credit losses model that replaces the current incurred loss impairment model.
- IFRS 16 “Leases”, effective from annual periods beginning on or after 1 January 2019, This standard replaces the current guidance in IAS 17 and is a far-reaching change in accounting by lessees in particular. Under IAS 17, lessees were required to make a distinction between a finance lease (on balance sheet) and an operating lease (off balance sheet). IFRS 16 now requires lessees to recognise a lease liability reflecting future lease payments and a ‘right-of-use asset’ for virtually all lease contracts. The IASB has included an optional exemption for certain short-term leases and leases of low-value assets; however, this exemption can only be applied by lessees. For lessors, the accounting stays almost the same. However, as the IASB has updated the guidance on the definition of a lease (as well as the guidance on the combination and separation of contracts), lessors will also be affected by the new standard. At the very least, the new accounting model for lessees is expected to impact negotiations between lessors and lessees. Under IFRS 16, a contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

**2.3 Comparative Information and Restatement of Prior Period Consolidated Financial Statements**

In order to allow the determination of financial position and performance, the Group's condensed consolidated financial statements are prepared in comparison with the previous period. In order to comply with the presentation of condensed consolidated financial statements the current period when deemed necessary, comparative information is restated, and material differences are presented. The Group has made some restatements regarding “Transaction Under Common Control” in order to conform to current period financial statements for prior periods. The nature of the restatement and amounts are as follows:

As per the principle related to “Accounting for business combinations under common control” the Public Oversight Accounting and Auditing Standards Authority issued in the Official Gazette dated 21 July 2013, business combinations under common control shall be accounted through restating previous period's financial statements via the pooling of interest method. The Group management restated only its interim condensed consolidated balance sheet as at 31 December 2015 and the interim condensed consolidated statements of comprehensive income and cash flows for the six-month period ended at 30 June 2015 for the transactions made under common control (details explained in Note 1) to fulfil the economic decision-making needs of financial statement users, because of the impracticability, within the scope of TAS 8. Effect of the restatements are shown below.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (cont'd)**

**2.3 Comparative Information and Restatement of Prior Period Consolidated Financial Statements (cont'd)**

	<b>Reported Previous Period</b>	<b>31 December 2015</b>	<b>Effects of Restatement</b>	<b>Restated</b>
<b>Current Assets</b>	<b>2,418,802.807</b>	<b>1,046,015.301</b>		<b>3,464,818.108</b>
Cash and cash equivalents	1,319,138.698	25,249.184		1,344,387.882
Financial Investments	704.437	-		704.437
Trade Receivables	648,516.627	114,884.637		763,401.264
Other Receivables	30,821.174	792,771.898		823,593.072
Inventories	234,137.771	84,366.205		318,503.976
Prepaid Expenses	149,529.118	18,513.176		168,042.294
Corporate Income Tax Assets	-	825.280		825.280
Other Current Assets	35,954.982	9,404.921		45,359.903
<b>Non-Current Assets</b>	<b>1,507,784.747</b>	<b>216,012.473</b>		<b>1,723,797.220</b>
Financial Investments	765,334.184	-		765,334.184
Trade Receivables	6,196.664	-		6,196.664
Other Receivables	173,437	3,474		176,911
Investment Properties	11,865.000	1,039.161		12,904.161
Property, Plant and Equipment	678,525.362	212,951.945		891,477.307
Intangible Assets	1,495.673	313,204		1,808.877
Prepaid Expenses	28,562.349	(6)		28,562.343
Deferred Tax Assets	15,627.892	1,704.695		17,332.587
Other Non-Current Assets	4,186	-		4,186
<b>TOTAL ASSETS</b>	<b>3,926,587.554</b>	<b>1,262,027.774</b>		<b>5,188,615.328</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (cont'd)**

**2.3 Comparative Information and Restatement of Prior Period Consolidated Financial Statements (cont'd)**

	<b>Reported Previous Period</b>	<b>31 December 2015</b>	<b>Effects of Restatement</b>	<b>Restated</b>
<b>Current Liabilities</b>		<b>653.505.104</b>	<b>1.130.786.950</b>	<b>1.784.292.054</b>
Short Term Financial Liabilities		92.987.409	831.967.137	924.954.546
Short Term Portion of Long-Term Financial Liabilities		19.921.073	14.914.746	34.835.819
Trade Payables		474.424.217	119.462.451	593.886.668
Employee Benefit Related Liabilities		20.844.357	6.486.690	27.331.047
Other Payables		1.375.545	89.462.391	90.837.936
Current Income Tax Liabilities		8.251.757	1.262.631	9.514.388
Short Term Provisions		25.272.122	25.990.381	51.262.503
Other Current Liabilities		10.428.624	41.240.523	51.669.147
<b>Non-Current Liabilities</b>		<b>1.633.652.466</b>	<b>174.032.458</b>	<b>1.807.684.924</b>
Long Term Financial Liabilities		1.570.188.333	165.132.604	1.735.320.937
Long Term Provisions		28.539.483	8.899.854	37.439.337
Deferred Tax Liabilities		34.924.650	-	34.924.650
<b>SHAREHOLDERS' EQUITY</b>		<b>1.639.429.984</b>	<b>(42.791.634)</b>	<b>1.596.638.350</b>
<b>Equity Attributable To Equity Holders' of the Parent</b>		<b>1.528.628.848</b>	<b>(141.862.799)</b>	<b>1.386.766.049</b>
Share Capital		342.000.000	-	342.000.000
Inflation Adjustments on Equity Items		108.056.201	-	108.056.201
Accumulated Other Comprehensive Income not to be Reclassified Under Profit and Loss				
- Actuarial Loss on Post-Employment Termination		(373.480)	(37.156)	(410.636)
- Investment Property Valuation Funds		5.231.735	-	5.231.735
Accumulated Other Comprehensive Income to be Reclassified Under Profit and Loss				
- Financial Assets Valuation Fund		539.968.646	-	539.968.646
Restricted Reserves Appropriated from Profits		112.116.833	-	112.116.833
Retained Earnings		161.340.007	(179.323.961)	(17.983.954)
Net Profit For The Period		260.288.906	37.498.318	297.787.224
<b>Non-Controlling Interest</b>		<b>110.801.136</b>	<b>99.071.165</b>	<b>209.872.301</b>
<b>TOTAL LIABILITIES AND EQUITY</b>		<b>3.926.587.554</b>	<b>1.262.027.774</b>	<b>5.188.615.328</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (cont'd)**

**2.3 Comparative Information and Restatement of Prior Period Consolidated Financial Statements (cont'd)**

<b>Statements of income 30 June 2015</b>	<b>Reported Previous Period</b>	<b>Effects of Restatement</b>	<b>Restated Previous Period</b>
	<b>1 January- 30 June 2015</b>		<b>1 January- 30 June 2015</b>
Revenue	1.510.908.383	404.878.509	1.915.786.892
Cost of Sales (-)	(1.169.268.204)	(305.199.693)	(1.474.467.897)
<b>GROSS PROFIT FROM OPERATIONS</b>	<b>341.640.179</b>	<b>99.678.816</b>	<b>441.318.995</b>
Research Expenses (-)	(3.568.423)	(58.709)	(3.627.132)
Marketing, Sales and Distribution Expenses (-)	(127.851.485)	(60.639.429)	(188.490.914)
General Administrative Expenses (-)	(38.356.430)	(15.718.886)	(54.075.316)
Other Operating Income	41.604.427	14.995.233	56.599.660
Other Operating Expenses (-)	(26.469.802)	(15.905.148)	(42.374.950)
<b>OPERATING PROFIT FROM MAIN OPERATIONS</b>	<b>186.998.466</b>	<b>22.351.877</b>	<b>209.350.343</b>
Income from Investment Activities	200.481.555	169.366.202	369.847.757
Expenses from Investment Activities (-)	(64.648.887)	(1.600)	(64.650.487)
<b>OPERATING PROFIT BEFORE FINANCIAL INCOME AND EXPENSES</b>	<b>322.831.134</b>	<b>191.716.479</b>	<b>514.547.613</b>
Financial Income	23.815.710	-	23.815.710
Financial Expenses (-)	(204.835.804)	(166.611.724)	(371.447.528)
<b>PROFIT BEFORE TAX</b>	<b>141.811.040</b>	<b>25.104.755</b>	<b>166.915.795</b>
<b>Tax Expense</b>	<b>(25.781.039)</b>	<b>(2.837.597)</b>	<b>(28.618.636)</b>
Tax on Income (-)	(33.248.998)	(3.234.026)	(36.483.024)
Deferred Tax Income	7.467.959	396.429	7.864.388
<b>PROFIT FOR THE PERIOD</b>	<b>116.030.001</b>	<b>22.267.158</b>	<b>138.297.159</b>
<b>Other Comprehensive Income:</b>			
<b>Items not to be Reclassified Under Profit and Loss</b>	<b>218.070</b>	-	<b>218.070</b>
Actuarial Loss on Post-Employment Termination Benefit Obligation	272.588	-	272.588
Deferred tax effect	(54.518)	-	(54.518)
<b>Items to be Reclassified Under Profit and Loss</b>	<b>(1.138.499)</b>	-	<b>(1.138.499)</b>
Change in Revaluation Funds of Financial Assets	(1.198.420)	-	(1.198.420)
Deferred tax effect	59.921	-	59.921
<b>OTHER COMPREHENSIVE EXPENSE</b>	<b>(920.429)</b>	-	<b>(920.429)</b>
<b>TOTAL COMPREHENSIVE INCOME</b>	<b>115.109.572</b>	<b>22.267.158</b>	<b>137.376.730</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (cont'd)**

**2.3 Comparative Information and Restatement of Prior Period Consolidated Financial Statements (cont'd)**

<b>Statements of income 31 March 2015</b>	<b>Reported Previous Period</b>	<b>Effects of Restatement</b>	<b>Restated Previous Period</b>
	<b>1 January-31 March 2015</b>		<b>1 January- 31 March 2015</b>
Revenue	789.717.435	191.085.286	980.802.721
Cost of Sales (-)	(605.168.009)	(145.525.185)	(750.693.194)
<b>GROSS PROFIT FROM OPERATIONS</b>	<b>184.549.426</b>	<b>45.560.101</b>	<b>230.109.527</b>
Research Expenses (-)	(1.593.280)	(19.293)	(1.612.573)
Marketing, Sales and Distribution Expenses (-)	(80.358.839)	(29.158.142)	(109.516.981)
General Administrative Expenses (-)	(19.438.023)	(6.790.186)	(26.228.209)
Other Operating Income	25.104.384	10.696.437	35.800.821
Other Operating Expenses (-)	(16.614.825)	(4.485.293)	(21.100.118)
<b>OPERATING PROFIT FROM MAIN OPERATIONS</b>	<b>91.648.843</b>	<b>15.803.624</b>	<b>107.452.467</b>
Income from Investment Activities	126.067.006	131.173.717	257.240.723
Expenses from Investment Activities (-)	(54.178.560)	(1.596)	(54.180.156)
<b>OPERATING PROFIT BEFORE FINANCIAL INCOME AND EXPENSES</b>	<b>163.537.289</b>	<b>146.975.745</b>	<b>310.513.034</b>
Financial Income	17.521.454	-	17.521.454
Financial Expenses (-)	(126.510.109)	(128.861.922)	(255.372.031)
<b>PROFIT BEFORE TAX</b>	<b>54.548.634</b>	<b>18.113.823</b>	<b>72.662.457</b>
<b>Tax Expense</b>	<b>(11.044.875)</b>	<b>(1.940.289)</b>	<b>(12.985.164)</b>
Tax on Income (-)	(17.607.311)	(2.125.317)	(19.732.628)
Deferred Tax Income	6.562.436	185.028	6.747.464
<b>PROFIT FOR THE PERIOD</b>	<b>43.503.759</b>	<b>16.173.534</b>	<b>59.677.293</b>
<b>Other Comprehensive Income:</b>			
<b>Items not to be Reclassified Under Profit and Loss</b>	<b>117.513</b>	-	<b>117.513</b>
Actuarial Loss on Post-Employment Termination Benefit Obligation	146.891	-	146.891
Deferred tax effect	(29.378)	-	(29.378)
<b>Items to be Reclassified Under Profit and Loss</b>	<b>(2.191.611)</b>	-	<b>(2.191.611)</b>
Change in Revaluation Funds of Financial Assets	(2.306.959)	-	(2.306.959)
Deferred tax effect	115.348	-	115.348
<b>OTHER COMPREHENSIVE EXPENSE</b>	<b>(2.074.098)</b>	-	<b>(2.074.098)</b>
<b>TOTAL COMPREHENSIVE INCOME</b>	<b>41.429.661</b>	<b>16.173.534</b>	<b>57.603.195</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**3. BUSINESS COMBINATIONS**

The Company purchased 20.250.000 shares of İstanbul Gıda Dış Ticaret A.Ş. from Yıldız Holding A.Ş., who is 100% shareholder, for an amount of TRY 43 million as of 31 March 2016. The net assets acquired and the effects of transaction in equity are presented as follows:

<b>Net Assets within the Scope of Consolidation</b>	<b>Asset/(Liability)</b>
<b>Current Assets</b>	
Cash and cash equivalents	2.107.616
Trade receivables	180.630.937
Other receivables	1.061.196.715
Other current assets	21.474.982
<b>Non-Current Assets</b>	
Tangible and intangible assets (Net)	2.882.635
Other non-current assets	1.707.255
<b>Current Liabilities</b>	
Financial liabilities	(877.541.939)
Trade payables	(155.346.116)
Other current liabilities	(57.421.414)
<b>Non-Current Liabilities</b>	
Financial liabilities	(145.809.229)
Other non-current liabilities	(4.132.149)
<b>Net Assets added into the scope of consolidation</b>	<b>29.749.293</b>
Total share of the Group ownership	100,0%
The portion of the net assets to Group	29.749.293
Cash paid for the acquisition	(43.000.000)
<b>Net Equity Impact from the acquisition of subsidiary</b>	<b>(13.250.707)</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**3. BUSINESS COMBINATIONS (cont'd)**

The Company purchased 51.0% shares of UI Egypt B.V., operating in Netherlands, from Yıldız Holding A.Ş. for an amount of USD 30 million as of 31 March 2016. As a result of the transaction, the Company has gained the controlling power in UI Egypt B.V. and Hi Food for Advanced Food Industries, which UI Egypt B.V. has 90% shares. The net assets acquired and the effects of transaction in equity are presented as follows:

<b>Net Assets within the Scope of Consolidation</b>	<b>Asset/(Liability)</b>
<b>Current Assets</b>	
Cash and cash equivalents	2.488.891
Trade receivables	10.833.046
Other receivables	5.195.245
Other current assets	36.779.487
<b>Non-Current Assets</b>	
Tangible and intangible assets (Net)	112.375.536
<b>Current Liabilities</b>	
Financial liabilities	(20.065.284)
Trade payables	(16.867.164)
Other current liabilities	(6.367.205)
<b>Non-Current Liabilities</b>	
Financial liabilities	(19.686.374)
Other non-current liabilities	(20.084.669)
<b>Net Assets added into the scope of consolidation</b>	<b>84.601.509</b>
Minority shares	8.481.038
Total share of the Group ownership	51,0%
The portion of the net assets to Group	38.821.440
Cash paid for the acquisition	(86.199.000)
<b>Net Equity Impact from the acquisition of subsidiary</b>	<b>(47.377.560)</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**3. BUSINESS COMBINATIONS (cont'd)**

The Company purchased 100.0% shares of Sabourne Investments Limited from Yıldız Holding A.Ş. for an amount of USD 50 million as of 27 June 2016. As a result of the transaction, the Company has gained the controlling power in Food Manufacturers' Company, which Sabourne Investments Limited. has 55.0% shares and the controlling power in Food Manufacturers' Company for Distribution, which Food Manufacturers' Company has 95.0% shares. The net assets acquired and the effects of transaction in equity are presented as follows:

<b>Net Assets within the Scope of Consolidation</b>	<b>Asset/(Liability)</b>
<b>Current Assets</b>	
Cash and cash equivalents	20.739.660
Trade receivables	44.777.045
Other receivables	745.081
Other current assets	68.509.347
<b>Non-Current Assets</b>	
Tangible and intangible assets (Net)	99.047.045
<b>Current Liabilities</b>	
Financial liabilities	(7.063.661)
Trade payables	(75.796.136)
Other current liabilities	(27.658.240)
<b>Non-Current Liabilities</b>	
Other non-current liabilities	(5.968.579)
<b>Net Assets added into the scope of consolidation</b>	<b>117.331.562</b>
Minority shares	53.291.094
Total share of the Group ownership	100,0%
The portion of the net assets to Group	64.040.468
Cash paid for the acquisition	(145.275.000)
<b>Net Equity Impact from the acquisition of subsidiary</b>	<b>(81.234.532)</b>

**4. SEGMENTAL INFORMATION**

The Group's core business activities are manufacturing and marketing of biscuit, chocolate, chocolate coated biscuit, wafer, and cake. The reports reviewed routinely by the decision makers of the Group comprise consolidated numbers of Ülker Bisküvi Sanayi A.Ş. and its subsidiaries.

Since the Group has operations in only one production area and the magnitude of foreign operations is under limits which is mentioned TFRS 8 and the decision makers use the consolidated reports, segmental reporting in accordance with TFRS 8 have not been provided in the accompanying consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**5. CASH AND CASH EQUIVALENTS**

	<b>30 June 2016</b>	<b>31 December 2015</b>
Cash	834.852	324.344
Demand deposits	39.241.127	28.881.703
Time deposits (*)	<u>1.705.638.319</u>	<u>1.315.181.835</u>
	<b><u>1.745.714.298</u></b>	<b><u>1.344.387.882</u></b>

(\*) All of time deposits consist of overnights (31 December 2015: TRY 1.315.181.835).

Details of time deposits are shown below:

<b>Currency Type</b>	<b>Annual Weighted Average Effective Interest Rate (%)</b>	<b>Maturity</b>	<b>30 June 2016</b>
			<b>30 June 2016</b>
TRY	11,50%	July 2016	344.858.618
USD	2,04%	July 2016	1.135.189.941
EUR	1,20%	July 2016	<u>225.589.760</u>
			<b><u>1.705.638.319</u></b>

<b>Currency Type</b>	<b>Annual Weighted Average Effective Interest Rate (%)</b>	<b>Maturity</b>	<b>31 December 2015</b>
			<b>31 December 2015</b>
EUR	1,59%	January 2016	533.399.795
USD	2,47%	January 2016	<u>781.782.040</u>
		<b><u>1.315.181.835</u></b>	

**6. FINANCIAL INVESTMENTS**

<b>Short Term Financial Investments:</b>		<b>30 June 2016</b>	<b>31 December 2015</b>
		<b>30 June 2016</b>	<b>31 December 2015</b>
Available for sale financial assets		582.728	704.437
		<b><u>582.728</u></b>	<b><u>704.437</u></b>
<b>Long Term Financial Investments:</b>		<b>30 Haziran 2016</b>	<b>31 Arahık 2015</b>
Available for sales financial assets		768.270.313	765.334.184
		<b><u>768.270.313</u></b>	<b><u>765.334.184</u></b>
<b>Long Term Available for Sale Financial Investments</b>	<b>%</b>	<b>30 June 2016</b>	<b>31 December 2015</b>
G New, Inc	12,20%	196.711.611	12,20%
Godiva Belgium BVBA	19,23%	537.772.863	19,23%
BİM Birleşik Mağazalar A.Ş.	0,20%	33.585.721	0,20%
Other		200.118	200.118
		<b><u>768.270.313</u></b>	<b><u>765.334.184</u></b>

Available for sale financial assets are presented at their fair values. The after tax difference belonging to equity holder of TRY 542.525.618 as of 30 June 2016 (30 June 2015: TRY 314.509.908) in the fair values of such assets has directly been presented in other comprehensive income under equity.

As the expected value gaps for available for sale financial assets of TRY 200.118 (31 December 2015: TRY 200.118) that are not traded in an active market are high and expected values are not reliably measured, these have been presented at historical cost in accompanying consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**7. FINANCIAL LIABILITIES**

	<b>30 June 2016</b>	<b>31 December 2015</b>
Short Term Liabilities	602.053.225	924.954.546
Short Term Portion of Long Term Liabilities	22.638.717	34.835.819
Long Term Liabilities	1.776.743.299	1.735.320.937
	<b>2.401.435.241</b>	<b>2.695.111.302</b>
<b><u>Short Term Liabilities</u></b>	<b>30 June 2016</b>	<b>31 December 2015</b>
Bank Loans	591.595.961	924.954.546
Non-Trade Payables to Related Parties (Note 21)	10.457.264	-
	<b>602.053.225</b>	<b>924.954.546</b>
<b><u>Short Term Portion of Long Term Liabilities</u></b>	<b>30 June 2016</b>	<b>31 December 2015</b>
Bank Loans	22.450.642	34.472.820
Financial Lease Payables	188.075	362.999
	<b>22.638.717</b>	<b>34.835.819</b>
<b><u>Long Term Liabilities</u></b>	<b>30 June 2016</b>	<b>31 December 2015</b>
Bank Loans	1.776.677.654	1.735.254.707
Financial Lease Payables	65.645	66.230
	<b>1.776.743.299</b>	<b>1.735.320.937</b>

The syndication loan has received as of 26 November 2014. Details of Group's syndication loans are as follows;

Syndication loan consists of two credit trenches which are USD 284.500.000 and EUR 211.823.840. 26 international banks joined to the syndication. Effective interest rate for both credit trenches is Libor + 2.75% and the maturity date is November 2017. Principal payments of the loans are repaid at maturity with semi-annual interest payments.

The covenants which belong to syndication loan are as follows:

- a) **Leverage:** The ratio of the consolidated net debt at balance sheet date to the last twelve months consolidated EBITDA (Earnings before interest, tax, depreciation and amortization) in the valid period should not be over 3 to 1.
- b) **Interest Coverage:** Consolidated interest coverage ratio of the Group should be at least 3 to 1.

In current year, the consolidated financial statements of the Group comply with the covenants of the syndication loan agreement.

**Bank Loans:**

**30 June 2016**

<b>Currency</b>	<b>Maturity</b>	<b>Annual Effective Weighted Average</b>		
		<b>Interest Rate (%)</b>	<b>Short Term</b>	<b>Long Term</b>
TRY	July 2016	Spot-% 12,68	22.764.568	203.500.000
EUR	July 2016-June 2020	% 2,76	20.723.229	740.255.506
USD	July 2016-November 2017	% 3,46	569.631.810	828.448.188
	November 2016-			
EGP	September 2019	% 14,00	2.038.010	4.473.960
SAR	August 2016	% 1,53	9.346.250	-
			<b>624.503.867</b>	<b>1.776.677.654</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**7. FINANCIAL LIABILITIES (cont'd)**

**31 December 2015**

<u>Currency</u>	<u>Maturity</u>	<u>Annual Effective Weighted Average Interest Rate (%)</u>	<u>Short Term</u>	<u>Long Term</u>
TRY	January 2016-July 2016	Spot	1.398.009	-
EUR	February 2016-June 2020	% 2,76	84.733.636	750.209.544
USD	January 2016- November 2017	% 3,18	855.399.919	978.876.603
EGP	November 2016- September 2019	% 14,00	10.832.140	6.168.560
SAR	August 2016	% 1,43	7.063.662	-
			<b>959.427.366</b>	<b>1.735.254.707</b>

The maturity detail of the bank loans is as follows:

	<b>30 June 2016</b>	<b>31 December 2015</b>
to be paid within 1 year	624.503.867	959.427.366
to be paid within 1-2 years	1.703.678.424	1.663.088.205
to be paid within 2-3 years	54.543.110	27.348.086
to be paid within 3-4 years	14.456.120	25.682.363
to be paid within 4-5 years	4.000.000	19.136.053
	<b>2.401.181.521</b>	<b>2.694.682.073</b>

**Financial Lease Payables:**

The detail of short term financial lease payables is as follows:

<b>Short-Term Financial Lease Payables</b>	<b>30 June 2016</b>	<b>31 December 2015</b>
Financial lease payables	200.335	362.999
Deferred financial lease payables (-)	(12.260)	-
	<b>188.075</b>	<b>362.999</b>

**Long-Term Financial Lease Payables**

	<b>30 June 2016</b>	<b>31 December 2015</b>
Financial lease payables	67.738	468.398
Deferred financial lease payables (-)	(2.093)	(402.168)
	<b>65.645</b>	<b>66.230</b>

The maturity detail of the financial lease payables is as follows:

	<b>30 June 2016</b>	<b>31 December 2015</b>
to be paid within 1 year	188.075	362.999
to be paid within 1-2 years	65.645	66.230
	<b>253.720</b>	<b>429.229</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**8. TRADE RECEIVABLES AND PAYABLES**

	<b>30 June 2016</b>	<b>31 December 2015</b>
<b>Short Term Due from Related Parties</b>		
Due from related parties (Note 21) (net)	532.913.132	572.853.651
	<b>532.913.132</b>	<b>572.853.651</b>
<b>Other Trade Receivables</b>		
Trade receivables (net)	168.371.852	194.387.255
Notes receivables (net)	799.143	1.105.172
Provision for doubtful receivables	(5.333.069)	(4.944.814)
	<b>163.837.926</b>	<b>190.547.613</b>
<b>Total Short Term Trade Receivables</b>	<b>696.751.058</b>	<b>763.401.264</b>
	<b>30 June 2016</b>	<b>31 December 2015</b>
<b>Long Term Due from Related Parties</b>		
Due from related parties (Note 21)	6.220.760	6.196.664
<b>Total Long Term Trade Receivables</b>	<b>6.220.760</b>	<b>6.196.664</b>

Trade receivables are disclosed at discounted net realizable value using the effective yield method. Net realizable value has been calculated over discount rate of 12.5% (2015: 12.9%) based on the Group's cash sales. The provision for trade receivables is provided for based on the estimated irrecoverable amounts from the sale of goods, determined by reference to past default experience.

The movement of the allowance for doubtful receivables as of 30 June 2016 and 2015 is as follows:

	<b>1 January- 30 June 2016</b>	<b>1 January- 30 June 2015</b>
Opening balance	(4.944.814)	(1.550.365)
Charge for the period	(411.980)	(140.629)
Currency translation adjustments	22.072	-
Collections	1.653	7.686
Closing balance	<b>(5.333.069)</b>	<b>(1.683.308)</b>
<b>Short Term Trade Payables</b>	<b>30 June 2016</b>	<b>31 December 2015</b>
Due to related parties (Note 21) (net)	255.724.837	309.288.490
Trade payables (net)	203.340.929	284.598.178
	<b>459.065.766</b>	<b>593.886.668</b>

Trade payables are disclosed at discounted net realizable value using the effective yield method. Net realizable value has been calculated over discount rate of 12.5% (2015: 12.9%) based on the Group's cash sales.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**9. OTHER RECEIVABLES AND PAYABLES**

	<b>30 June 2016</b>	<b>31 December 2015</b>
<b>Short Term Other Receivables</b>		
Due from related parties (Note 21)	150.803	786.329.934
Short term other receivables	37.620.738	37.263.138
	<b>37.771.541</b>	<b>823.593.072</b>
<b>Other Short Term Receivables</b>		
VAT receivables	15.338.696	15.463.094
Compensation receivables from insurance entity	11.498.656	13.319.191
Deposits and guarantees given	1.054.030	1.185.520
Receivables from employees	667.358	1.278.441
Other	9.061.998	6.016.892
	<b>37.620.738</b>	<b>37.263.138</b>
<b>Other Long Term Receivables</b>		
Deposits and guarantees given	178.097	176.911
	<b>178.097</b>	<b>176.911</b>

**10. INVENTORIES**

Inventory details are as follows:

	<b>30 June 2016</b>	<b>31 December 2015</b>
Raw materials	137.888.329	134.649.764
Work in progress	12.982.596	11.270.572
Finished goods	134.774.738	158.396.641
Trade goods	1.281.465	-
Other inventories	22.529.651	22.970.612
Allowance for impairment on inventory (-)	(9.190.017)	(8.783.613)
	<b>300.266.762</b>	<b>318.503.976</b>

Inventory is presented on cost value and allowance for impairment is booked for inventory valuing lower than cost.

The movement of allowance for impairment on inventory for the periods ended 30 June 2016 and 2015 are below:

	<b>1 January- 30 June 2016</b>	<b>1 January- 30 June 2015</b>
Opening balance	(8.783.613)	(3.555.919)
Charge for the period	(2.767.005)	(807.257)
Provisions released	2.360.601	470.557
Closing balance	<b>(9.190.017)</b>	<b>(3.892.619)</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED  
FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR  
THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

---

**11. INVESTMENT PROPERTIES**

	<b>1 January- 30 June 2016</b>	<b>1 January- 30 June 2015</b>
Opening balance	12.904.161	12.056.876
Charge for the period	(10.784)	(10.784)
<b>Closing balance</b>	<b>12.893.377</b>	<b>12.046.092</b>

The fair value of the Group's investment properties at 31 December 2015 and 2014 have been calculated on the basis of a valuation carried out at that date by 31 December 2015 and 1 December 2014, by independent valuers not related to the Group. EVA Gayrimenkul Değerleme Danışmanlık A.Ş. is one of the accredited independent valuers by Capital Markets Board of Turkey, and has appropriate qualifications and recent experience in the valuation of properties in the relevant locations. The valuation, which conforms to International Valuation Standards, based on market evidence of transaction prices for similar properties.

As explained details in Note 1, the increase in fair value of additions arising from "Transaction Under Common Control" is expected not material impact on the condensed consolidated financial statements by Group management. The Group management will reevaluate fair value increase of additions at the year-end.

The rent income earned by the Group from its investment properties amounting to TRY 531.270 (30 June 2015:TRY 562.778) within the current period. Direct operating expenses arising from the investment properties in the current period amounting to TRY 37.441 (30 June 2015: TRY 38.805).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira (“TRY”) unless otherwise stated.)

**12. PROPERTY, PLANT AND EQUIPMENT**

Movements of tangible assets between 1 January 2016 – 30 June 2016 are as follows:

<b>Cost</b>	<b>1 January 2016</b>	<b>Addition</b>	<b>Disposal</b>	<b>Transfers (Note 13)</b>	<b>Currency translation adjustments</b>	<b>30 June 2016</b>
Land	16.458.202	163.277	-	-	(1.653.113)	14.968.366
Land improvements	7.803.257	60.711	-	137.695	-	8.001.663
Buildings	291.432.723	2.733.639	-	198.382	(2.528.979)	291.835.765
Machinery, plant and equipment	1.081.200.410	2.827.014	(2.099.319)	30.842.420	(10.452.360)	1.102.318.165
Vehicles	4.194.313	1.228.330	(93.285)	-	(216.161)	5.113.197
Furniture and fixtures	57.395.634	1.236.192	(119.038)	637.393	(248.562)	58.901.619
Leasehold improvements	19.930.469	195.713	-	2.168.410	-	22.294.592
Other tangible assets	4.847.122	200.613	-	-	(21.046)	5.026.689
Construction in progress	164.296.470	126.181.286	-	(34.049.336)	(4.878.651)	251.549.769
	<b>1.647.558.600</b>	<b>134.826.775</b>	<b>(2.311.642)</b>	<b>(65.036)</b>	<b>(19.998.872)</b>	<b>1.760.009.825</b>

<b>Accumulated Depreciation</b>	<b>1 January 2016</b>	<b>Charge for the period</b>	<b>Disposal</b>	<b>Transfers</b>	<b>Currency translation adjustments</b>	<b>30 June 2016</b>
Land improvements	(3.250.227)	(193.829)	-	-	-	(3.444.056)
Buildings	(98.063.139)	(4.668.295)	-	-	386.446	(102.344.988)
Machinery, plant and equipment	(592.709.768)	(30.866.713)	1.189.274	-	4.457.234	(617.929.973)
Vehicles	(3.149.816)	(175.275)	93.285	-	106.437	(3.125.369)
Furniture and fixtures	(43.818.632)	(2.149.030)	119.038	-	144.372	(45.704.252)
Leasehold improvements	(12.061.210)	(798.925)	-	-	-	(12.860.135)
Other tangible assets	(3.028.501)	(158.642)	-	-	12.463	(3.174.680)
	<b>(756.081.293)</b>	<b>(39.010.709)</b>	<b>1.401.597</b>	<b>-</b>	<b>5.106.952</b>	<b>(788.583.453)</b>
<b>Net Book Value</b>		<b>891.477.307</b>				<b>971.426.372</b>

From depreciation and amortization expenses, TRY 36.289.267 (30 June 2015: TRY 33.787.216) is included in cost of goods sold, TRY 152.067 (30 June 2015: TRY 150.245) is included in research and development expenses, TRY 730.368 (30 June 2015: TRY 1.128.317) is included in marketing and selling expenses and TRY 2.345.142 (30 June 2015: TRY 1.714.138) is included in general administrative expenses. There is no collateral or mortgage on fixed assets. There is no fixed assets acquired through leasing in the current period. In 2016, the Group has capitalized TRY 331.437 interest and TRY 4.746.004 foreign exchange losses with regards to borrowings and accounted for such borrowing costs under construction in progress (30 June 2015: TRY 269.505 interest, TRY 1.030.867 foreign exchange losses).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**12. PROPERTY, PLANT AND EQUIPMENT (cont'd)**

Movement of tangible assets between 1 January - 30 June 2015 are as follows:

Cost	1 January 2015	Addition	Disposal	Transfers (Note 13)	30 June 2015
Land	3.386.659	7.930.325	(10.000)	-	11.306.984
Land improvements	7.191.876	28.515	-	-	7.220.391
Buildings	240.912.607	332.866	-	26.000	241.271.473
Machinery, plant and equipment	789.041.606	4.707.846	(1.685.621)	16.591.002	808.654.833
Vehicles	931.045	-	(24.526)	-	906.519
Furniture and fixtures	47.871.465	1.540.815	(244.304)	482.093	49.650.069
Leasehold improvements	16.891.825	58.303	(125.920)	-	16.824.208
Other tangible assets	1.396	-	-	-	1.396
Construction in progress	49.810.642	49.529.850	(359.244)	(17.191.529)	81.789.719
	<b>1.156.039.121</b>	<b>64.128.520</b>	<b>(2.449.615)</b>	<b>(92.434)</b>	<b>1.217.625.592</b>

Accumulated Depreciation	1 January 2015	Charge for the period	Disposal	Transfers	30 June 2015
Land improvements	(2.893.688)	(235.063)	-	-	(3.128.751)
Buildings	(74.104.335)	(4.750.265)	-	-	(78.854.600)
Machinery, plant and equipment	(459.348.671)	(28.846.391)	1.039.033	-	(487.156.029)
Vehicles	(809.255)	(20.902)	11.753	-	(818.404)
Furniture and fixtures	(38.246.315)	(1.720.488)	177.088	-	(39.789.715)
Leasehold improvements	(10.918.860)	(624.084)	34.130	-	(11.508.814)
Other tangible assets	(1.396)	-	-	-	(1.396)
	<b>(586.322.520)</b>	<b>(36.197.193)</b>	<b>1.262.004</b>	<b>-</b>	<b>(621.257.709)</b>
<b>Net Book Value</b>	<b><u>569.716.601</u></b>				<b><u>596.367.883</u></b>

There is no fixed assets acquired through leasing in the related period. There is no collateral or mortgage on fixed assets.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**12. PROPERTY, PLANT AND EQUIPMENT (cont'd)**

The useful lives of tangible assets are as follows:

	<b>Useful life</b>
Land improvements	10 - 50 years
Buildings	25 - 50 years
Machinery and equipment	4 - 15 years
Vehicles	4 - 10 years
Furniture and fixtures	3 - 10 years
Other tangible assets	4 - 10 years
Leasehold improvements	During rent period

**13. INTANGIBLE ASSETS**

Movements of intangible assets between 1 January 2016 – 30 June 2016 are as follows:

<b>Cost</b>	<b>1 January 2016</b>	<b>Addition</b>	<b>Disposals</b>	<b>Transfers (Note 12)</b>	<b>30 June 2016</b>
Rights	2.442.307	78.251	-	65.036	2.585.594
Development costs	675.004	-	-	-	675.004
Other intangible assets	2.636.278	6.021	(53.625)	-	2.588.674
	<b>5.753.589</b>	<b>84.272</b>	<b>(53.625)</b>	<b>65.036</b>	<b>5.849.272</b>
<b>Accumulated amortization</b>	<b>1 January 2016</b>	<b>Charge for the Period</b>	<b>Disposals</b>	<b>Transfers</b>	<b>30 June 2016</b>
Rights	(2.028.211)	(144.704)	-	-	(2.172.915)
Development costs	(222.292)	(33.751)	-	-	(256.043)
Other intangible assets	(1.694.209)	(316.896)	53.625	-	(1.957.480)
	<b>(3.944.712)</b>	<b>(495.351)</b>	<b>53.625</b>	<b>-</b>	<b>(4.386.438)</b>
<b>Net Book Value</b>	<b><u>1.808.877</u></b>				<b><u>1.462.834</u></b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**13. INTANGIBLE ASSETS (cont'd)**

Movements of intangible assets between 1 January 2015 – 30 June 2015 are as follows:

Cost	1 January 2015	Addition	Disposals	Transfers (Note 12)	30 June 2015
Rights	2.444.195	-	(210.242)	-	2.233.953
Development costs	675.004	-	-	-	675.004
Other intangible assets	1.858.963	517.042	-	92.434	2.468.439
	<b>4.978.162</b>	<b>517.042</b>	<b>(210.242)</b>	<b>92.434</b>	<b>5.377.396</b>

  

Accumulated amortization	1 January 2015	Charge for the Period	Disposals	Transfers	30 June 2015
Rights	(1.928.752)	(171.315)	210.242	18.200	(1.871.625)
Development costs	(121.041)	(67.501)	-	-	(188.542)
Other intangible assets	(1.104.905)	(333.123)	-	(18.200)	(1.456.228)
	<b>(3.154.698)</b>	<b>(571.939)</b>	<b>210.242</b>	<b>-</b>	<b>(3.516.395)</b>
<b>Net Book Value</b>	<b>1.823.464</b>				<b>1.861.001</b>

The intangible assets are amortized on a straight-line basis over their estimated useful lives.

	<b>Useful Life</b>
Rights	2 - 15 years
Other intangible assets	2 - 12 years

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**14. PROVISIONS, CONTINGENT ASSETS AND LIABILITIES**

**Guarantees given:**

(Foreign currency amounts are shown in original currencies)

	<b>30 June 2016</b>		<b>31 December 2015</b>	
	<b>TRY</b>	<b>USD</b>	<b>TRY</b>	<b>USD</b>
A) GPMs (Guarantees, Provisions and Mortgages) given for companies own legal personality	41.508.060	64.900	44.046.870	64.900
B) GPMs given on behalf of fully consolidated companies	-	-	-	-
C) GPMs given for continuation of its economic activities on behalf of third parties	-	-	-	-
D) Total amount of other GPMs	-	147.000.000	50.000.000	147.000.000
i. Total amount GPMs given on behalf of the majority shareholder	-	147.000.000	50.000.000	147.000.000
(*)				
ii. Total amount of GPMs given to on behalf of other group companies which	-	-	-	-
are not in scope of B and C				
iii. Total amount of GPMs given on behalf of third parties which are not in scope of consolidation	-	-	-	-
<b>Total</b>	<b>41.508.060</b>	<b>147.064.900</b>	<b>94.046.870</b>	<b>147.064.900</b>

(\*) The GPMs provided on behalf of majority shareholder come from the bank loans obtained in previous years and the closing process for USD balance is still in progress as of balance sheet date considering the maturities of loans. Meanwhile, TRY balance has been closed at the current period. The ratio of other CPMs to the Group's equity as of 30 June 2016 is 29.0% (31 December 2015: 31.2%).

**15. REVENUE AND COST OF SALES**

The detail of the operational income is as follows:

	<b>1 January- 30 June 2016</b>	<b>1 April- 30 June 2016</b>	<b>1 January- 30 June 2015</b>	<b>1 April- 30 June 2015</b>
Domestic sales	2.141.067.291	1.044.412.668	1.987.386.240	966.366.277
Export sales	409.803.952	208.499.712	484.984.520	244.892.864
Sales returns and discounts (-)	(570.325.873)	(278.664.481)	(556.583.868)	(276.274.970)
<b>Revenue (net)</b>	<b>1.980.545.370</b>	<b>974.247.899</b>	<b>1.915.786.892</b>	<b>934.984.171</b>
Cost of goods sold (-)	(1.401.835.472)	(682.395.920)	(1.317.338.043)	(638.840.814)
Cost of trade goods sold (-)	(104.064.768)	(57.635.843)	(157.129.854)	(84.933.889)
<b>Cost of Sales</b>	<b>(1.505.900.240)</b>	<b>(740.031.763)</b>	<b>(1.474.467.897)</b>	<b>(723.774.703)</b>
<b>Gross Profit</b>	<b>474.645.130</b>	<b>234.216.136</b>	<b>441.318.995</b>	<b>211.209.468</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**16. EXPENSES BY NATURE**

The detail of operating expenses is as follows:

	<b>1 January- 30 June 2016</b>	<b>1 April- 30 June 2016</b>	<b>1 January- 30 June 2015</b>	<b>1 April- 30 June 2015</b>
<b>Research Expenses</b>				
Personnel expenses	(1.914.143)	(945.117)	(1.866.354)	(744.181)
Materials used	(1.096.232)	(491.882)	(681.942)	(437.738)
Depreciation and amortization expenses	(152.067)	(76.217)	(150.245)	(79.327)
Other	(1.122.578)	(689.027)	(928.591)	(753.313)
	<b>(4.285.020)</b>	<b>(2.202.243)</b>	<b>(3.627.132)</b>	<b>(2.014.559)</b>
<b>Marketing Expenses</b>				
Marketing operating expenses	(141.362.429)	(64.710.561)	(158.521.030)	(62.429.891)
Personnel expenses	(27.197.841)	(10.829.272)	(22.329.542)	(11.338.921)
Depreciation and amortization expenses	(730.368)	(326.087)	(1.128.317)	(584.602)
Rent expenses	(3.256.048)	(2.881.907)	(2.904.945)	(2.655.547)
Other	(9.043.654)	(5.177.754)	(3.607.080)	(1.964.972)
	<b>(181.590.340)</b>	<b>(83.925.581)</b>	<b>(188.490.914)</b>	<b>(78.973.933)</b>
<b>General Administration Expenses</b>				
Operating expenses (*)	(20.749.489)	(12.281.170)	(19.842.339)	(9.408.468)
Personnel expenses	(26.619.223)	(15.174.946)	(26.225.217)	(14.101.453)
Depreciation and amortization expenses	(2.345.142)	(1.158.243)	(1.714.138)	(813.434)
Consultancy expenses	(2.128.252)	(981.490)	(1.057.786)	(565.599)
Other	(8.341.597)	(4.594.336)	(5.235.836)	(2.958.153)
	<b>(60.183.703)</b>	<b>(34.190.185)</b>	<b>(54.075.316)</b>	<b>(27.847.107)</b>

(\*) The operating expenses of the Group mainly comprise management support, information technology and administration expenses that are charged by Yıldız Holding A.Ş.

**17. FINANCIAL INCOME**

	<b>1 January- 30 June 2016</b>	<b>1 April- 30 June 2016</b>	<b>1 January- 30 June 2015</b>	<b>1 April- 30 June 2015</b>
Foreign exchange gain	93.769.078	13.359.019	23.815.710	6.294.256
Other	2.320.025	1.152.419	-	-
	<b>96.089.103</b>	<b>14.511.438</b>	<b>23.815.710</b>	<b>6.294.256</b>

**18. FINANCIAL EXPENSES**

	<b>1 January- 30 June 2016</b>	<b>1 April- 30 June 2016</b>	<b>1 January- 30 June 2015</b>	<b>1 April- 30 June 2015</b>
Foreign exchange losses from financing	(97.869.942)	(50.638.456)	(335.315.577)	(96.872.470)
Interest expenses	(40.449.797)	(18.805.272)	(32.213.850)	(16.733.719)
Other	(3.239.605)	(1.558.684)	(3.918.101)	(2.469.308)
	<b>(141.559.344)</b>	<b>(71.002.412)</b>	<b>(371.447.528)</b>	<b>(116.075.497)</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**19. TAX ASSETS AND LIABILITIES**

The Group accounts deferred tax assets and liabilities for temporary timing differences rooted from differences between legal financial statements and financial statements prepared in accordance with UFRS. The differences in question are caused generally by the fact that some profit and loss accounts come up in different periods in legal financial statements and financial statements prepared in accordance with UFRS. These differences are specified below.

Turkish tax legislation does not permit a parent company and its subsidiary to file a consolidated tax return. Therefore, deferred tax positions of the firms with deferred tax assets is netted against those with deferred tax liabilities and reflected on a separate-entity basis.

The rate applied in the calculation of deferred tax assets and liabilities for entities in Turkey and Saudi Arabia is 20% (2015: 20%) for entity in Egypt 25% (2015: 25%).

**Deferred tax bases:**

	<b>30 June 2016</b>	<b>31 December 2015</b>	<b>30 June 2016</b>	<b>31 December 2015</b>
Indexation and useful life differences of tangible and intangible assets	-	-	166.413.666	163.530.691
Investment properties valuation differences	-	-	11.308.157	11.284.955
Marketable securities valuation differences	-	-	577.299.948	569.361.288
Profit margin elimination on inventories	(1.211.720)	(121.610)	-	-
Discount of trade receivables / payables (net)	(2.893.375)	(1.773.475)	-	-
Allowance of employee termination benefits	(33.132.550)	(29.412.870)	-	-
Provision of doubtful receivables	(629.175)	(444.845)	-	-
Previous year losses	(832.325)	(2.305.687)	-	-
Provision for lawsuits	(5.521.183)	(4.312.538)	-	-
Impairment on inventories	(4.556.860)	(5.312.140)	-	-
Unused vacation provision	(11.785.260)	(9.771.720)	-	-
Other	(13.232.471)	(17.863.961)	6.846.482	14.534.512
	<b>(73.794.919)</b>	<b>(71.318.846)</b>	<b>761.868.253</b>	<b>758.711.446</b>

**Deferred tax (assets) / liabilities:**

	<b>30 June 2016</b>	<b>31 December 2015</b>	<b>30 June 2016</b>	<b>31 December 2015</b>
Indexation and useful life differences of tangible and intangible assets	-	-	33.282.733	32.706.138
Investment properties valuation differences	-	-	565.408	564.248
Marketable securities valuation differences	-	-	28.864.997	28.468.064
Profit margin elimination on inventories	(242.344)	(24.322)	-	-
Discount of trade receivables / payables (net)	(578.675)	(354.695)	-	-
Allowance of employee termination benefits	(6.626.510)	(5.882.574)	-	-
Provision of doubtful receivables	(125.835)	(88.969)	-	-
Previous year losses	(166.465)	(461.137)	-	-
Provision for lawsuits	(1.104.237)	(862.508)	-	-
Impairment on inventories	(911.372)	(1.062.428)	-	-
Unused vacation provision	(2.357.052)	(1.954.344)	-	-
Investment allowance	(31.131.087)	(32.736.325)	-	-
Other	(2.646.494)	(3.572.792)	1.369.296	2.853.707
	<b>(45.890.071)</b>	<b>(47.000.094)</b>	<b>64.082.434</b>	<b>64.592.157</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**19. TAX ASSETS AND LIABILITIES (cont'd)**

	<b>1 January - 30 June 2016</b>	<b>1 January - 30 June 2015</b>
<b><u>Movement of Deferred Tax Liabilities:</u></b>		
Opening balance	17,592,063	21,343,928
Taxes netted against funds recognised under equity	(120,585)	(5,403)
Deferred tax (loss)/gain	720,885	(7,864,388)
<b>Closing balance</b>	<b>18,192,363</b>	<b>13,474,137</b>
<b><u>Corporate Tax</u></b>		

The Company and its Turkish subsidiaries are subject to Turkish corporate taxes. Provision is made in the accompanying financial statements for the estimated charge based on the Group's results for the period.

Corporate tax is applied on taxable corporate income, which is calculated from the statutory accounting profit by adding back non-deductible expenses, and by deducting dividends received from resident companies, other exempt income and investment incentives utilized.

The effective tax rate in 30 June 2016 is 20% (2015: 20%).

In Turkey, advance tax returns are filed on a quarterly basis. The advance corporate income tax rate is 20% in 2016 (31 December 2015: 20%).

Losses are allowed to be carried five years maximum to be deducted from the taxable profit of the following years. However, losses occurred cannot be deducted from the profit occurred in the prior years retroactively.

In Turkey, there is no procedure for a final and definitive agreement on tax assessments. Companies file their tax returns between 1st -25th of April following the close of the accounting year to which they relate. The companies with special accounting periods, file their tax returns between 1st-25th of fourth month after fiscal year end. Tax authorities may, however, examine such returns and the underlying accounting records and may revise assessments within five years.

In Turkey, the tax legislation does not permit to file a consolidated tax return. Therefore, provision for taxes, as reflected in the consolidated financial statements, has been calculated on a separate-entity basis.

Until 31 December 2018, Hi Food for Advanced Food Industries, the Group's subsidiary, is exempt from corporate tax for earnings gained from operating activities due to tax incentives made within the scope of foreign trade legislation. The corporation tax rate in Suudi Arabia where Food Manufacturers' Company, a subsidiary of the Group is 20%. (2015: 20%).

**Income withholding tax**

In addition to corporate taxes, companies should also calculate income withholding taxes and funds surcharge on any dividends distributed, except for companies receiving dividends who are Turkish residents and Turkish branches of foreign companies. Income withholding tax applied in between 24 April 2003 – 22 July 2006 is 10% and commencing from 23 July 2006, this rate has been changed to 15% upon the Council of Ministers' Resolution No: 2006/10731. Undistributed dividends incorporated in share capital are not subject to income withholding tax.

Provision for taxation as of 30 June 2016 and 31 December 2015 are as follows:

	<b>30 June 2016</b>	<b>31 December 2015</b>
Total corporate tax provision	(48,560,682)	(53,251,248)
Prepaid taxes and funds	20,958,729	43,736,860
Taxation in the balance sheet	<b>(27,601,953)</b>	<b>(9,514,388)</b>
	<b>1 January - 30 June 2016</b>	<b>1 January - 30 June 2015</b>
Current year corporate tax provision	47,301,572	36,483,024
Deferred tax income	720,885	(7,864,388)
Taxation in the income statement	<b>48,022,457</b>	<b>28,618,636</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**20. EARNINGS PER SHARE**

A summary of the Group's weighted average number of shares outstanding as of 30 June 2016 and 30 June 2015 and computation of earnings per share set out here as follows:

	<b>1 January - 30 June 2016</b>	<b>1 January - 30 June 2015</b>
Weighted average number of common stock outstanding	34.200.000.000	34.200.000.000
Net profit	177.992.394	122.044.887
<b>Basic Earnings Per Share (TRY 1 par value each)</b>	<b>0,52</b>	<b>0,36</b>

**21. BALANCES AND TRANSACTIONS WITH RELATED PARTIES**

a) The detail of receivables from related parties is as follows:

	<b>30 June 2016</b>	<b>31 December 2015</b>
Trade receivables	539.133.892	579.050.315
Non-trade receivables	150.803	786.329.934
	<b>539.284.695</b>	<b>1.365.380.249</b>

The detail of trade and non-trade receivables is as follows:

	<b>30 June 2016</b>		<b>31 December 2015</b>	
	<b>Trade</b>	<b>Non-Trade</b>	<b>Trade</b>	<b>Non-Trade</b>
<i><b>Principle Shareholders</b></i>				
Yıldız Holding A.Ş.	-	-	-	546.424.794
<i><b>Other Companies Controlled by the Principle Shareholder and Ülker Family</b></i>				
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	262.628.430	-	257.572.982	-
Pasifik Tük. Ürün. Satış Ve Ticaret A.Ş.	194.415.801	-	186.668.812	-
Teközel Gıda T.Sağ. Mrk. Hiz. San. Tic. A.Ş.	27.675.880	-	44.551.045	-
Misbis Gıda San. Tic. A.Ş.	2.052.542	-	3.608.941	7.297.899
Önem Gıda San. ve Tic. A.Ş.	211.769	-	363.154	-
Natura Gıda San. ve Tic. A.Ş.	1.207.811	-	427.371	-
Besler Gıda ve Kimya San. ve Tic. A.Ş.	-	-	-	232.607.241
Rekor Gıda Paz. San. ve Tic. A.Ş.	-	-	41.768.628	-
Other	<b>50.941.659</b>	<b>150.803</b>	<b>44.089.382</b>	<b>-</b>
	<b>539.133.892</b>	<b>150.803</b>	<b>579.050.315</b>	<b>786.329.934</b>

The Group's trade receivables from related parties mainly arise from sales to Horizon Hızlı Tüketicim Ürünleri Pazarlama Satış ve Tic. A.Ş. and Pasifik Tük. Ürün. Satış ve Ticaret A.Ş. those make the sale and distribution of products throughout Turkey.

The detail of advances given to related parties is as follow:

	<b>30 June 2016</b>	<b>31 December 2015</b>
Önem Gıda San. ve Tic. A.Ş.	103.146.776	112.601.084
	<b>103.146.776</b>	<b>112.601.084</b>

b) The detail of payables to related parties is as follows

	<b>30 June 2016</b>	<b>31 December 2015</b>
Trade payables	255.724.837	309.288.490
Non-trade payables	-	86.239.625
	<b>255.724.837</b>	<b>395.528.115</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**21. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (cont'd)**

The detail of payables to related parties is as follows:

	<b>30 June 2016</b>		<b>31 December 2015</b>	
	<b>Trade</b>	<b>Non-Trade</b>	<b>Trade</b>	<b>Non-Trade</b>
<b>Principle Shareholder</b>				
Yıldız Holding A.Ş.	20.539.485	-	20.751.901	-
<b>Other Companies Controlled by the Principle Shareholder and Ülker Family</b>				
Önem Gıda San. ve Tic. A.Ş.	163.035.415	-	199.902.805	-
Besler Gıda ve Kimya San. Tic. A.Ş.	35.091.197	-	42.355.406	-
Marsa Yağ San. ve Tic. A.Ş.	13.820.222	-	15.197.181	-
Maia International	-	-	-	86.199.000
CCC Gıda San. ve Tic. A.Ş.	5.487.797	-	10.295.813	-
Northstar Innovation A.Ş.	122.099	-	1.774.659	-
Other	17.628.622	-	19.010.725	40.625
	<b>255.724.837</b>	<b>-</b>	<b>309.288.490</b>	<b>86.239.625</b>

The detail of due to related parties as loan payable is as follows:

	<b>30 June</b>	<b>31 December</b>
	<b>2016</b>	<b>2015</b>
Yıldız Holding A.Ş.	10.457.264	-
	<b>10.457.264</b>	<b>-</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİŞKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira (“TRY”) unless otherwise stated.)

**21. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (cont’d)**

c) The detail of purchases from and sales to related parties is as follows

	<b>1 January - 30 June 2016</b>		<b>1 April - 30 June 2016</b>		<b>1 January - 30 June 2015</b>		<b>1 April - 30 June 2015</b>	
	<b>Purchases</b>	<b>Sales</b>	<b>Purchases</b>	<b>Sales</b>	<b>Purchases</b>	<b>Sales</b>	<b>Purchases</b>	<b>Sales</b>
<i>Other Companies Controlled by the Principle Shareholder and Ülker Family</i>								
Önem Gıda San. ve Tic. A.Ş.	533.195.161	190.663	251.240.798	141.354	472.836.355	4.698.024	205.110.867	3.868.576
Besler Gıda ve Kimya San. ve Tic. A.Ş.	85.302.507	80.160	42.279.084	-	95.629.288	116.987	47.288.159	75.935
Marsa Yağ San. ve Tic. A.Ş.	27.678.875	232.547	13.408.598	126.918	27.123.351	-	12.605.959	-
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	195.124	858.752.484	195.124	432.290.795	-	743.188.027	-	354.293.887
Ak Gıda San. ve Tic. A.Ş. (*)	-	-	-	-	96.761.984	311.613	55.427.871	156.217
Pendik Nişasta San. A.Ş.	23.790.207	-	10.552.092	-	15.283.860	-	7.435.644	-
CCC Gıda San. ve Tic. A.Ş.	11.674.671	60.672	4.773.131	47.538	16.340.691	141.543	7.484.168	4.542
Teközel Gıda Tem. Sağ. Mark. Hizm. A.Ş.	85.281	82.194.171	521	36.640.865	-	96.286.171	-	46.531.288
Pasifik Tüketicim Ürünleri Satış ve Tic. A.Ş.	-	430.609.352	-	206.790.949	1.228	378.305.812	1.228	177.465.468
Rekor Gıda Paz. San. ve Tic. A.Ş.	1.992.919	-	-	-	3.838	74.603.825	-	37.719.786
Other	46.483.022	116.511.257	29.601.036	64.724.102	43.145.713	85.090.604	26.099.676	41.691.141
	<b>730.397.767</b>	<b>1.488.631.306</b>	<b>352.050.384</b>	<b>740.762.521</b>	<b>767.126.308</b>	<b>1.382.742.606</b>	<b>361.453.572</b>	<b>661.806.840</b>

(\*) Ak Gıda San. ve Tic. A.Ş. has been classified as third party due to sold by Yıldız Holding A.Ş. on 1 July 2015. For this reason; purchases and sales amounts between 1 January 2015 – 30 June 2015 reported as related parties.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİŞKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**21. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (cont'd)**

d) The detail of income and expenses pertaining to interest, rent and services arising from transactions with related parties is as follows:

For the six month period ended on 30 June 2016:

	Rent Income	Rent Expense	Service Income	Service Expense	Interest Income and Foreign exchange gains	Interest Expense and Foreign exchange losses
<b>Principle Shareholder</b>						
Yıldız Holding A.Ş.	29.728	(948)	13.695	(58.299.265)	113.476.468	(76.916.607)
<b>Other Companies Controlled by the Principle Shareholder and Ülker Family</b>						
Besler Gıda ve Kimya San. ve Tic. A.Ş.	-	-	34.221	(400.554)	4.949.089	(6.213.164)
Hüner Pazarlama San. ve Tic. A.Ş.	337.392	-	253.724	(23.704)	-	-
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	38.216	(83.671)	647.322	(6.729.927)	-	-
Önem Gıda San. ve Tic. A.Ş.	628.935	(12.619)	1.357.661	(16.345.429)	167.772	(1.167.404)
Marsa Yağ San. ve Tic. A.Ş.	3.488	-	20.086	-	125.733	(26.427)
Pasifik Tüketicim Ürünleri Satış ve Tic. A.Ş.	78.881	-	44.166	(1.363.595)	-	-
Northstar Innovation A.Ş.	-	-	15.917	(129.034)	-	-
İzsal Gayrimenkul Geliştirme A.Ş.	14.976	(599.858)	3.734	(299.790)	-	-
Rekor Gıda Paz. San. ve Tic. A.Ş.	14.111	-	-	(29.914)	-	-
United Biscuits (UK) Ltd.	-	-	568.646	-	-	(74.151)
Other	8.464	(209.895)	629.809	(518.483)	1.417.513	(892.835)
	<b>1.154.191</b>	<b>(906.991)</b>	<b>3.588.981</b>	<b>(84.139.695)</b>	<b>120.136.575</b>	<b>(85.290.588)</b>

For the three month period between April- June 2016:

	Rent Income	Rent Expense	Service Income	Service Expense	Interest Income and Foreign exchange gains	Interest Expense and Foreign exchange losses
<b>Principle Shareholder</b>						
Yıldız Holding A.Ş.	14.864	(373)	4.317	(32.730.116)	54.163.124	(9.520.663)
<b>Other Companies Controlled by the Principle Shareholder and Ülker Family</b>						
Besler Gıda ve Kimya San. ve Tic. A.Ş.	-	-	34.221	-	4.815.453	(2.266.744)
Hüner Pazarlama San. ve Tic. A.Ş.	164.674	-	116.232	-	-	-
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	4.190	(40.761)	82.869	(4.355.119)	-	-
Önem Gıda San. ve Tic. A.Ş.	475.692	(10.669)	61.642	(9.369.684)	-	(683.193)
Marsa Yağ San. ve Tic. A.Ş.	1.765	-	10.697	-	21.592	-
Pasifik Tüketicim Ürünleri Satış ve Tic. A.Ş.	41.007	-	-	(735.160)	-	-
Northstar Innovation A.Ş.	-	-	15.917	(40.514)	-	-
İzsal Gayrimenkul Geliştirme A.Ş.	7.488	(289.982)	-	(146.335)	-	-
İstanbul Gıda Dış Tic. A.Ş.	-	-	-	-	-	-
Rekor Gıda Paz. San. ve Tic. A.Ş.	-	-	-	-	-	-
United Biscuits (UK) Ltd.	-	-	568.646	-	-	(74.151)
Other	2.362	(209.895)	197.003	(488.898)	477.127	(54.429)
	<b>712.042</b>	<b>(551.680)</b>	<b>1.091.544</b>	<b>(47.865.826)</b>	<b>59.477.296</b>	<b>(12.599.180)</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**21. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (cont'd)**

d) The detail of income and expenses pertaining to interest, rent and services arising from transactions with related parties is as follows:

For the six month period ended on 30 June 2015:

	Rent Income	Rent Expense	Service Income	Service Expense	Interest Income and Foreign exchange gains	Interest Expense and Foreign exchange losses
<b>Principle Shareholder</b>						
Yıldız Holding A.Ş.	63.263	(9.299)	1.014.256	(59.299.432)	249.018.906	(73.026.261)
<b>Other Companies Controlled by the Principle Shareholder and Ülker Family</b>						
Besler Gıda ve Kimya San. ve Tic. A.Ş.	-	-	422.300	(1.120.711)	29.545.819	(953.129)
Hüner Pazarlama San. ve Tic. A.Ş.	316.593	-	194.692	(141.528)	-	-
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	33.768	(77.056)	144.403	(2.198.119)	-	-
Önem Gıda San. ve Tic. A.Ş.	555.916	(2.366)	2.952.056	(1.814.539)	45.126	(769.415)
Marsa Yağ San. ve Tic. A.Ş.	3.240	-	13.724	-	112.884	(1.180.195)
Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.	52.126	-	137.878	(728.043)	-	-
Northstar Innovation A.Ş.	-	-	54.043	(2.707)	-	-
İzsal Gayrimenkul Geliştirme A.Ş.	12.752	(602.665)	8.177	(300.662)	-	-
Rekor Gıda Paz. San. ve Tic. A.Ş.	90.564	-	377.502	(190.182)	-	-
Natura Gıda San. ve Tic. A.Ş.	-	-	62.110	-	-	-
Other	18.182	-	2.025.575	(1.122.378)	4.771.464	(2.969.040)
	<b>1.146.404</b>	<b>(691.386)</b>	<b>7.406.716</b>	<b>(66.918.301)</b>	<b>283.494.199</b>	<b>(78.898.040)</b>

For the three month period between April- June 2015:

	Rent Income	Rent Expense	Service Income	Service Expense	Interest Income and Foreign exchange gains	Interest Expense and Foreign exchange losses
<b>Principle Shareholder</b>						
Yıldız Holding A.Ş.	32.691	(14.315)	337.173	(29.603.331)	102.057.237	(12.794.498)
<b>Other Companies Controlled by the Principle Shareholder and Ülker Family</b>						
Besler Gıda ve Kimya San. ve Tic. A.Ş.	-	-	327.835	(909.032)	5.603.350	(111.577)
Hüner Pazarlama San. ve Tic. A.Ş.	159.015	-	93.614	(67.000)	-	-
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	29.115	(75.204)	45.404	(989.012)	-	-
Önem Gıda San. ve Tic. A.Ş.	406.891	(566)	1.684.470	(1.440.934)	29.047	(378.163)
Marsa Yağ San. ve Tic. A.Ş.	1.638	-	8.673	-	-	(301.755)
Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.	27.158	-	16.791	(221.141)	-	-
Northstar Innovation A.Ş.	-	-	50.380	-	-	-
İzsal Gayrimenkul Geliştirme A.Ş.	6.276	(342.792)	3.841	(128.503)	-	-
Rekor Gıda Paz. San. ve Tic. A.Ş.	46.376	-	162.877	(87.804)	-	-
Natura Gıda San. ve Tic. A.Ş.	-	-	15.796	-	-	-
Other	9.501	-	1.203.922	(645.089)	1.572.413	(1.639.239)
	<b>718.661</b>	<b>(432.877)</b>	<b>3.950.776</b>	<b>(34.091.846)</b>	<b>109.262.047</b>	<b>(15.225.232)</b>

e) Benefits provided to members of BOD and key management personnel:

	30 June 2016	30 June 2015
Fees and other short term benefits	8.716.999	6.715.986
	<b>8.716.999</b>	<b>6.715.986</b>

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**22. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS**

*Foreign currency risk management*

As of balance sheet date, the foreign currency denominated assets and liabilities of monetary and non-monetary items are as follows:

	<b>2016</b>						
	<b>TRY</b>	<b>Equivalent</b>	<b>USD</b>	<b>EUR</b>	<b>GBP</b>	<b>CHF</b>	<b>DKK</b>
1. Trade Receivables	129.538.015	25.804.866	15.190.989	1.600.168	-	-	-
2a. Monetary Financial Assets	1.394.135.847	388.751.180	83.348.441	537.344	24.555	28.857	
2b. Non-Monetary Financial Assets	-	-	-	-	-	-	
3. Other	4.396.111	796.421	635.658	14.134	-	-	
<b>4. CURRENT ASSETS</b>	<b>1.528.069.973</b>	<b>415.352.467</b>	<b>99.175.088</b>	<b>2.151.646</b>	<b>24.555</b>	<b>28.857</b>	
5. Trade receivables	6.220.760	2.149.834	-	-	-	-	
6a. Monetary Financial Assets	88.471	30.464	100	-	-	-	
6b. Non-Monetary Financial Assets	-	-	-	-	-	-	
7. Other	14.304.487	1.057.341	3.494.361	12.312	-	-	
<b>8. NON-CURRENT ASSETS</b>	<b>20.613.718</b>	<b>3.237.639</b>	<b>3.494.461</b>	<b>12.312</b>	-	-	
<b>9. TOTAL ASSETS</b>	<b>1.548.683.691</b>	<b>418.590.106</b>	<b>102.669.549</b>	<b>2.163.958</b>	<b>24.555</b>	<b>28.857</b>	
10. Trade Payables	108.769.692	22.458.666	12.988.363	555.804	4.409	-	
11. Financial Liabilities	590.355.040	196.859.210	6.467.117	-	-	-	
12a. Other Monetary Financial Liabilities	2.378.512	95.646	343.486	258.745	-	-	
12b. Other Non-Monetary Financial Liabilities	6.738.761	1.841.291	438.477	1.485	-	-	
<b>13. SHORT-TERM LIABILITIES</b>	<b>708.242.005</b>	<b>221.254.813</b>	<b>20.237.443</b>	<b>816.034</b>	<b>4.409</b>	<b>-</b>	
14. Trade Payables	-	-	-	-	-	-	
15. Financial Liabilities	1.568.703.694	286.303.631	231.012.204	-	-	-	
16a. Other Monetary Financial Liabilities	-	-	-	-	-	-	
16b. Other Non-Monetary Financial Liabilities	-	-	-	-	-	-	
<b>17. LONG-TERM LIABILITIES</b>	<b>1.568.703.694</b>	<b>286.303.631</b>	<b>231.012.204</b>	-	-	-	
<b>18. TOTAL LIABILITIES</b>	<b>2.276.945.699</b>	<b>507.558.444</b>	<b>251.249.647</b>	<b>816.034</b>	<b>4.409</b>	<b>-</b>	
19. Net foreign currency asset/liability position	(728.262.008)	(88.968.338)	(148.580.098)	1.347.924	20.146	28.857	
20. Net foreign currency asset / liability position of monetary items	(740.223.845)	(88.980.809)	(152.271.640)	1.322.963	<b>20.146</b>	<b>28.857</b>	

(1+2a+5+6a-10-11-12a-14-15-16a)

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**22. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENT (cont'd)**

*Foreign currency risk management (cont'd)*

	2015					
	TRY Equivalent	USD	EUR	CHF	GBP	DKK
1. Trade Receivables	146.118.886	33.928.693	13.177.409	-	1.301.017	-
2a. Monetary Financial Assets	2.097.627.237	537.550.534	167.980.798	8.426	190.601	59.113
2b. Non-Monetary Financial Assets	704.436	242.274	-	-	-	-
3. Other	4.523.312	1.313.947	217.227	3.364	644	-
4. CURRENT ASSETS	<b>2.248.973.871</b>	<b>573.035.448</b>	<b>181.375.434</b>	<b>11.790</b>	<b>1.492.262</b>	<b>59.113</b>
5. Trade Receivables	6.196.663	2.131.195	-	-	-	-
6a. Monetary Financial Assets	88.636	30.375	100	-	-	-
6b. Non-Monetary Financial Assets	-	-	-	-	-	-
7. Other	25.028.612	1.634.213	5.997.235	416.750	-	-
8. NON-CURRENT ASSETS	<b>31.313.911</b>	<b>3.795.783</b>	<b>5.997.335</b>	<b>416.750</b>	-	-
9. TOTAL ASSETS	<b>2.280.287.782</b>	<b>576.831.231</b>	<b>187.372.769</b>	<b>428.540</b>	<b>1.492.262</b>	<b>59.113</b>
10. Trade Payables	82.868.802	11.694.730	13.568.610	61.322	1.295.150	-
11. Financial Liabilities	940.133.556	294.194.497	26.665.923	-	-	-
12a. Other Monetary Financial	89.009.301	136.555	27.557.348	-	243.222	-
12b. Other Non-monetary Financial	12.777.763	3.167.266	1.121.044	-	1.486	-
13. CURRENT LIABILITIES	<b>1.124.789.422</b>	<b>309.193.048</b>	<b>68.912.925</b>	<b>61.322</b>	<b>1.539.858</b>	-
14. Trade Payables	-	-	-	-	-	-
15. Financial Liabilities	1.729.086.145	336.661.371	236.093.134	-	-	-
16a. Other Monetary Financial	-	-	-	-	-	-
16b. Other Non-monetary Financial	-	-	-	-	-	-
17. NON-CURRENT LIABILITIES	<b>1.729.086.145</b>	<b>336.661.371</b>	<b>236.093.134</b>	-	-	-
18. TOTAL NON-CURRENT	<b>2.853.875.567</b>	<b>645.854.419</b>	<b>305.006.059</b>	<b>61.322</b>	<b>1.539.858</b>	-
19. Net foreign currency liability position	(573.587.785)	(69.023.188)	(117.633.290)	367.218	(47.596)	59.113
20. Net foreign currency of monetary items (1+2a+5+6a-10-11-12a-14-15-16a)	<b>(591.066.382)</b>	<b>(69.046.356)</b>	<b>(122.726.708)</b>	<b>(52.896)</b>	<b>(46.754)</b>	<b>59.113</b>

The Group's export and import balances for the six months period are presented below:

	1 January – 30 June 2016	1 January – 30 June 2015
Total exports	409.803.952	484.984.520
Total imports	115.617.595	68.048.443

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**22. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENT (cont'd)**

Foreign currency risk sensitivity

The Group is exposed to foreign exchange risk arising primarily from USD and EUR. In the table below, the foreign currency sensitivity of the Company arising from 10% change in US dollar and EUR rates. 10% is the rate used when reporting to senior management of the Company. This rate is the anticipated rate change of the Company's senior management. Sensitivity analysis includes only the monetary items in foreign currency at year end and shows the effect of 10% increase in USD and in EUR foreign currency rates. Negative value implies the effect of 10% increase in USD and in EUR foreign currency rates against TRY on the decrease in the net profit.

	<b>30 June 2016</b>		<b>30 June 2015</b>	
	Income / Expense		Income / Expense	
	Appreciation of foreign currency	Depreciation of foreign currency	Appreciation of foreign currency	Depreciation of foreign currency
In case of 10% appreciation of USD against TRY				
1 - US Dollar net asset / liability	(25.747.487)	25.747.487	39.603.277	(39.603.277)
2- Part of hedged from US Dollar risk (-)	-	-	-	-
<b>3- US Dollar net effect (1+2)</b>	<b>(25.747.487)</b>	<b>25.747.487</b>	<b>39.603.277</b>	<b>(39.603.277)</b>
In case of 10% appreciation of EUR against TRY				
4 – Euro net asset / liability	(48.793.924)	48.793.924	(59.316.413)	59.316.413
5 – Part of hedged from Euro risk (-)	-	-	-	-
<b>6- Euro net effect (4+5)</b>	<b>(48.793.924)</b>	<b>48.793.924</b>	<b>(59.316.413)</b>	<b>59.316.413</b>
<b>Total (3 + 6)</b>	<b>(74.541.411)</b>	<b>74.541.411</b>	<b>(19.713.136)</b>	<b>19.713.136</b>

**23. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT**

Fair Value of Financial Assets

Fair value measurements by level of the following fair value measurement hierarchy is as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).

Level 3: Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs)

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2016**

(Amounts expressed in Turkish Lira ("TRY") unless otherwise stated.)

**23. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (cont'd)**

Fair Value of Financial Assets (cont'd)

The classification of the Company's financial assets and liabilities at fair value is as follows:

	<b>30 June 2016</b>	<b>Level of fair value as of reporting date</b>		
		<b>Level 1 TRY</b>	<b>Level 2 TRY</b>	<b>Level 3 TRY</b>
Financial assets				
Financial assets for which fair value differences reflected through profit and loss				
- Shares	582.728	582.728	-	-
Financial assets for which fair value differences reflected through comprehensive income statement				
- Shares	768.070.195	33.585.721	734.484.474	-
<b>Total</b>	<b>768.652.923</b>	<b>34.168.449</b>	<b>734.484.474</b>	<b>-</b>
Financial assets	<b>31 December 2015</b>	<b>Level of fair value as of reporting date</b>		
		<b>Level 1 TRY</b>	<b>Level 2 TRY</b>	<b>Level 3 TRY</b>
Financial assets for which fair value differences reflected through profit and loss				
- Shares	704.437	704.437	-	-
Financial assets for which fair value differences reflected through comprehensive income statement				
- Shares	765.134.066	30.649.592	734.484.474	-
<b>Total</b>	<b>765.838.503</b>	<b>31.354.029</b>	<b>734.484.474</b>	<b>-</b>

**24. EVENTS AFTER THE BALANCE SHEET DATE**

There is no event after balance sheet date.